Malignant Biliary Obstruction
Malignant biliary obstruction is the blockage of bile duct flow caused by cancerous tumors—most commonly pancreatic, cholangiocarcinoma, or ampullary neoplasms—leading to obstructive jaundice and cholestasis.
Malignant biliary obstruction (MBO) refers to obstruction of the biliary tract by cancer growth within or around the biliary tract. [1]
Let's break the name down:
- "Malignant" = caused by cancer (as opposed to benign causes like gallstones or strictures)
- "Biliary" = relating to bile or the bile ducts (from Latin bilis = bile)
- "Obstruction" = blockage of flow
The key consequence is that bile — which is produced by hepatocytes and normally drains through the intrahepatic ducts → common hepatic duct → common bile duct → ampulla of Vater → duodenum — cannot reach the intestine. This causes conjugated (direct) hyperbilirubinaemia and the clinical syndrome of obstructive jaundice.
Clinical Pearl
Painless progressive obstructive jaundice in an elderly patient is malignant biliary obstruction until proven otherwise. [2] This is a classic exam stem and ward-round teaching point. The "painless" and "progressive" nature distinguishes it from gallstone disease, which typically causes episodic colicky pain.
2. Epidemiology
- MBO is not a single disease — it is a clinical syndrome caused by various malignancies. Epidemiology therefore depends on the underlying cause.
- Pancreatic cancer (the most common cause of MBO) is the 4th–5th leading cause of cancer death globally and has been rising in Hong Kong.
- Cholangiocarcinoma: Perihilar cholangiocarcinoma (Klatskin tumour) is the most common subtype (≈60%) [3]. Intrahepatic cholangiocarcinoma has been increasing in incidence worldwide.
- Hepatocellular carcinoma (HCC): The 5th most common cancer in Hong Kong and 3rd in cancer mortality [4]. HCC is disproportionately common in HK due to endemic hepatitis B.
- Gallbladder carcinoma: Female predominance (M:F = 1:2–3) [5]. 95% have co-existing gallstones.
- Recurrent pyogenic cholangitis (RPC) — also known as "Hong Kong disease" / oriental cholangiohepatitis [6] — is a significant risk factor for cholangiocarcinoma in the local population due to chronic biliary inflammation and intrahepatic stone disease.
3. Anatomy & Function of the Biliary System
Understanding the anatomy is absolutely essential to understanding where obstruction occurs and what it causes.
- Intrahepatic bile ducts: Small bile canaliculi between hepatocytes → interlobular ducts → segmental ducts → right and left hepatic ducts
- Common hepatic duct (CHD): Formed by confluence (bifurcation) of right and left hepatic ducts at the hepatic hilum
- Cystic duct: Drains the gallbladder and joins the CHD
- Common bile duct (CBD): Formed by junction of CHD + cystic duct. Approximately 7–8 cm long, runs in the hepatoduodenal ligament (free edge of lesser omentum), passes behind the first part of duodenum, through the head of pancreas
- Ampulla of Vater: Where CBD and main pancreatic duct converge, opening into the second part of the duodenum (D2) at the major duodenal papilla
- Sphincter of Oddi: Circular smooth muscle around the ampulla — controls bile and pancreatic juice flow into the duodenum
The biliary tree is divided into regions, and the level of obstruction determines which structures are dilated and which clinical features arise:
| Region | Anatomical Boundaries | Key Pathologies |
|---|---|---|
| Intrahepatic | Ducts proximal to CHD bifurcation | Intrahepatic cholangiocarcinoma, HCC, RPC, hepatic metastases |
| Perihilar (Hilar) | Between CHD bifurcation and cystic duct origin | Klatskin tumour, CA gallbladder, Mirizzi syndrome, porta hepatis lymphadenopathy, PSC, RPC |
| Mid-CBD | Between cystic duct origin and upper border of pancreas | CA CBD, CA head of pancreas, lymphadenopathy |
| Distal CBD | From upper border of pancreas to ampulla | Periampullary carcinoma (CA head of pancreas, CA ampulla, CA distal CBD, CA duodenum), chronic pancreatitis, choledochal cysts |
Why does it matter WHERE the obstruction is?
The level of obstruction determines:
- Which parts of the biliary tree are dilated on imaging (e.g., intrahepatic dilatation only vs. both intra- and extrahepatic)
- Whether the gallbladder is distended (obstruction below the cystic duct junction → GB distends = positive Courvoisier's sign)
- The surgical approach (Whipple's for distal, hepatectomy ± bile duct resection for perihilar, etc.)
- Whether jaundice occurs at all — obstruction of only ONE hepatic duct (e.g., just the right) will NOT cause jaundice because the contralateral lobe compensates by excreting bilirubin normally [8]
- The hepatoduodenal ligament (part of lesser omentum) contains the "portal triad": CBD (anterolateral), hepatic artery proper (anteromedial), portal vein (posterior). Tumours here can compress all three.
- The head of the pancreas wraps around the distal CBD — this is why even small pancreatic head tumours cause early biliary obstruction.
- The ampulla of Vater is the most distal point — tumours here present earliest with jaundice (and therefore have the best prognosis among periampullary carcinomas) because even tiny tumours obstruct the narrow ampullary lumen [5].
Understanding bile function explains the clinical consequences of obstruction:
| Bile Component | Function | Consequence When Obstructed |
|---|---|---|
| Bile salts | Emulsify dietary fats → enable fat absorption | Steatorrhoea (fatty, pale, foul-smelling stool), fat-soluble vitamin malabsorption (A, D, E, K) |
| Conjugated bilirubin | Excreted in bile → converted to urobilinogen/stercobilin in gut → gives stool its brown colour | Pale stool (no stercobilin), dark/tea-coloured urine (excess conjugated bilirubin spills into urine), jaundice |
| Cholesterol & phospholipids | Cholesterol excretion pathway | Cholesterol retention |
| IgA & antimicrobial factors | Mucosal defence in biliary tree | Biliary sepsis risk |
| Alkaline fluid | Neutralises gastric acid in duodenum | Impaired duodenal pH buffering |
4. Etiology (Causes of MBO)
4.1 Malignant Causes of Biliary Obstruction
These are the cancers that directly cause MBO. The lecture slides specifically list: [1] [9]
Pathology causing malignant biliary obstruction: [1]
- Carcinoma of duodenum
- Periampullary carcinoma
- Carcinoma of pancreas
- Lymphoma
- Carcinoma of gallbladder — cystic duct LN, direct infiltration of CBD, tumour fragments
- Cholangiocarcinoma at hilum, Klatskin tumour
- HCC — direct infiltration, compression, tumour fragments in CBD
Let me elaborate on each:
These four tumours are grouped because their presentation and management are similar [5]:
| Tumour | Mechanism of Obstruction | Key Features |
|---|---|---|
| CA head of pancreas | Direct compression/invasion of distal CBD as it passes through pancreatic head | Most common cause of MBO overall; 70% of pancreatic cancers are in the head [7] |
| CA ampulla of Vater | Obstruction at the ampullary orifice | Best prognosis among periampullary CAs — presents earliest because even small tumours obstruct the narrow ampulla [5] |
| CA distal CBD | Intrinsic obstruction of distal CBD | Relatively uncommon as isolated entity |
| CA duodenum | Invasion into ampulla or compression of distal CBD | Rare; may also cause duodenal obstruction |
- Definition: Carcinoma of the bile duct; > 90% are adenocarcinoma [3] [8]
- Klatskin tumour: Specifically refers to cholangiocarcinoma at the CHD bifurcation (hepatic confluence) — usually perihilar type [3]
- Mechanism: Direct intrinsic obstruction of the bile duct lumen
- Obstruction of the bifurcation of left and right hepatic duct → jaundice in early stage [8]
- Intrahepatic cholangiocarcinoma will NOT cause jaundice since bilirubin can be reabsorbed and re-excreted through unaffected parts of the liver [8]
- Characterised by slow growth, high rate of local invasion, mucin production, and tendency to invade perineural sheath and spread along nerves [8]
Bismuth-Corlette Classification (for perihilar cholangiocarcinoma): [3]
| Type | Description |
|---|---|
| I | Below CHD bifurcation |
| II | Reaching CHD bifurcation |
| IIIa | Involves CHD and right hepatic duct |
| IIIb | Involves CHD and left hepatic duct |
| IV | Involves CHD, RHD and LHD / Multicentric |
HCC causes MBO through several mechanisms [5]:
- Compression causing obstructive jaundice — usually when mass is situated near the confluence of left and right intrahepatic ducts
- From anterior liver = Segment 4/5
- From posterior liver = Caudate segment (uncommon)
- Spread to lymph nodes (porta hepatis) in liver hilum
- Direct infiltration of CBD
- Tumour fragments in CBD
This is a clinically useful framework — when you see the imaging, you determine the level of dilatation and then generate your differential [5]:
| Level | Malignant Causes | Benign Causes |
|---|---|---|
| Hilum | CA gallbladder, HCC, Klatskin's tumour, porta lymphadenopathy | Mirizzi syndrome, PSC, RPC |
| Mid-CBD | CA CBD, CA head of pancreas, lymphadenopathy | — |
| Distal CBD | Periampullary carcinoma | Bile duct strictures, choledochal cysts, pancreatic cysts, chronic pancreatitis |
These must be distinguished from MBO [5]:
- Choledocholithiasis (CBD stones) — most common cause of biliary obstruction overall
- Benign strictures: TB, autoimmune, iatrogenic (post-surgical), RPC
- Primary biliary cholangitis (PBC)
- Primary sclerosing cholangitis (PSC)
- Chronic pancreatitis / Pancreatic cysts
- Mirizzi syndrome — CHD obstruction caused by extrinsic compression from an impacted stone in Hartmann's pouch/cystic duct [12]
- Blood clot (haemobilia) / mucus / foreign body / tumour thrombus
Differentiating Stone vs Tumour — Key History Points
From the senior notes [2], important questions to differentiate:
- Stone: History of episodic colicky pain (waxing-waning), fever (cholangitis), fluctuating jaundice (stone moves = "ball-valve" effect), history of gallstones
- Tumour: Painless, progressive jaundice, weight loss, constitutional symptoms, new-onset diabetes (pancreatic CA), palpable gallbladder (Courvoisier's sign)
- Urine/stool changes: Both cause tea-coloured urine and pale stools, but in tumour obstruction these are progressive and persistent; in stone disease they may fluctuate
5. Risk Factors for the Underlying Malignancies
Since MBO is caused by various cancers, we must understand the risk factors for each:
| Category | Risk Factor | Mechanism |
|---|---|---|
| Cholestatic/Inflammatory | Primary sclerosing cholangitis (PSC) | Chronic biliary inflammation → dysplasia → carcinoma; strong association especially with perihilar disease. PSC strongly associated with ulcerative colitis |
| Recurrent pyogenic cholangitis (RPC) | Chronic intrahepatic stone disease → biliary stasis → recurrent inflammation | |
| Cholelithiasis / Hepatolithiasis | Chronic inflammation of bile ducts | |
| Congenital | Choledochal cysts / Caroli's disease | Biliary stasis + chronic inflammation from reflux of pancreatic juice + abnormalities in bile salt transporter proteins |
| Lynch syndrome (HNPCC) | Germline mutation in DNA mismatch repair genes → increased cancer risk | |
| Multiple biliary papillomatosis | Multiple adenomatous polyps in intrahepatic bile ducts | |
| Infectious | Parasitic infection (liver flukes) | Clonorchis sinensis and Opisthorchis viverrini from undercooked freshwater fish → adult worms inhabit biliary system → chronic inflammatory state → malignant transformation |
| Chronic liver disease (HBV, HCV) | Chronic hepatitis → cirrhosis → cholangiocarcinoma | |
| Chemical | Thorotrast (thorium dioxide) exposure | Historical radiological contrast agent — radioactive α-emitter retained in reticuloendothelial system |
| Metabolic | Obesity, DM, metabolic syndrome | Chronic inflammation, insulin resistance |
| Non-Modifiable | Modifiable |
|---|---|
| Advanced age | Smoking (3x risk) |
| Male sex | Chronic pancreatitis |
| Non-O blood group | Diabetes mellitus (new-onset DM can be early sign of occult pancreatic CA) |
| Family history / Hereditary syndromes (Lynch, BRCA1/2, Peutz-Jeghers, FAMMM) | Obesity, physical inactivity |
| Heavy alcohol | |
| High fat/protein diet, low fibre | |
| Pancreatic cysts (IPMN — most common neoplastic pancreatic cyst with high risk of malignant degeneration) |
- Gallstones (95% of patients have gallstones) — strongest risk factor; larger and symptomatic stones carry higher risk
- Gallbladder polyps > 1 cm — prophylactic cholecystectomy recommended
- Porcelain gallbladder — calcified GB wall from chronic cholecystitis → ALL porcelain gallbladders should be removed (absolute indication for cholecystectomy) [5]
- Primary sclerosing cholangitis
- Abnormal pancreaticobiliary junction — long common channel → reflux of pancreatic juice into biliary tree
- Choledochal cysts
- Any cause of cirrhosis: HBV (most common in HK), HCV, ALD, NAFLD, Wilson's disease, PBC, PSC
- HBV is carcinogenic even without cirrhosis (HBV DNA integration → direct DNA damage)
- Aflatoxin exposure
- Smoking, alcohol, obesity, DM
6. Pathophysiology
To understand what goes wrong, we first need to know what keeps things working normally [13]:
- Continuous flushing action of bile — physically washes away bacteria
- Bacteriostatic activity of bile salts — bile salts are inherently antimicrobial
- Biliary mucous and secretory IgA — anti-adherence factors preventing bacterial colonisation
- Sphincter of Oddi — acts as a mechanical barrier to ascending duodenal reflux and bacterial infection
When a tumour obstructs the biliary tree, a cascade of pathophysiological consequences follows:
6.3 Manifestations of Pathophysiological Disturbance
- Why? Vitamin K is a fat-soluble vitamin (along with A, D, E). Bile salts are required for fat emulsification and absorption in the small intestine. Without bile reaching the gut, fat-soluble vitamins cannot be absorbed.
- Vitamin K is a cofactor for hepatic synthesis of clotting factors II, VII, IX, X (and proteins C and S).
- Vitamin K deficiency → impaired clotting factor synthesis → coagulopathy → bleeding tendency
- This is a correctable coagulopathy — give parenteral (IV/IM) vitamin K (not oral, because oral vitamin K still requires bile salts for absorption!)
Exam Trap
Do NOT confuse the coagulopathy of obstructive jaundice (vitamin K deficiency — correctable with IV vitamin K) with the coagulopathy of liver failure (impaired synthetic function — NOT correctable with vitamin K alone because the hepatocytes themselves are damaged). The response to parenteral vitamin K is a useful clinical test to distinguish these.
Causes of mortality in MBO include: biliary sepsis, cancer cachexia, and liver failure. [9]
- Endotoxaemia — the liver normally clears gut-derived endotoxins (lipopolysaccharide from Gram-negative bacteria) via the reticuloendothelial system (Kupffer cells). In biliary obstruction, this function is impaired.
- Impaired reticuloendothelial function — Kupffer cells in the obstructed liver are dysfunctional
- Impaired cell-mediated immunity — obstructive jaundice suppresses T-cell and NK cell function
- Combined with loss of the biliary barrier (bile salts, IgA, sphincter of Oddi function), there is high susceptibility to ascending cholangitis and bacteraemia
The common organisms are [13]:
- Gram-negative: E. coli, Klebsiella pneumoniae, Enterobacter spp., Bacteroides fragilis
- Gram-positive: Enterococcus spp.
- If stent present: Pseudomonas (biofilm former on foreign bodies)
- Impaired protein synthesis — the obstructed, cholestatic liver has reduced synthetic function
- Malnutrition from cancer cachexia + fat malabsorption compounds this
- This is why MBO patients are high-risk surgical candidates [1]
- Prolonged biliary obstruction → secondary biliary cirrhosis
- Progressive hepatocyte damage from retained bile acids (which are cytotoxic)
- Combined with biliary sepsis → hepatocellular damage → liver failure
- Conjugated bilirubin and bile acids are directly nephrotoxic
- Endotoxaemia causes renal vasoconstriction
- Patients with obstructive jaundice are at high risk of post-operative acute kidney injury — this is why aggressive hydration and avoidance of nephrotoxins are critical peri-operatively
The lecture emphasises: operative risk and strategy to reduce the risk. [1]
The combination of:
- Coagulopathy (vitamin K deficiency)
- Immunosuppression (impaired reticuloendothelial function, impaired cell-mediated immunity)
- Impaired wound/anastomotic healing (poor protein synthesis)
- Renal vulnerability (cholemic nephrosis)
- Malnutrition (cancer cachexia + fat malabsorption)
- Liver dysfunction (cholestasis ± secondary biliary cirrhosis)
...makes these patients among the highest-risk in surgery. Perioperative optimisation is crucial.
7. Classification
As detailed in Section 4.1 above.
| Level | Imaging Findings | Key Causes |
|---|---|---|
| Intrahepatic | Dilated intrahepatic ducts ONLY; CBD normal | Intrahepatic CC, HCC |
| Hilar | Dilated intrahepatic ducts; CBD normal or mildly dilated; GB may not be distended | Klatskin tumour, CA GB, HCC near hilum |
| Distal | Dilated intrahepatic AND extrahepatic ducts; GB distended (Courvoisier's) | Periampullary CA, CA head of pancreas |
As detailed in Section 4.1B above. This classification guides surgical planning — determines how much liver and bile duct needs resection. [3]
The lecture slide specifically lists scenarios where a patient presents with both jaundice AND an epigastric mass:
Pathology producing jaundice and epigastric mass: [11]
- Hepatomegaly secondary to biliary obstruction
- Hepatomegaly due to metastases or HCC
- Lymph node metastases to the coeliac axis or porta hepatis
- Carcinoma of stomach with metastatic lymph node in the porta hepatis
- Distended stomach due to duodenal obstruction by tumour which obstructs the bile duct as well
8. Clinical Features
| Symptom | Pathophysiological Basis |
|---|---|
| Painless progressive jaundice | Gradual tumour growth → slowly progressive obstruction. Painless because there is no acute distension or inflammation (unlike gallstone colic). The jaundice is progressive because the tumour grows relentlessly. This is THE hallmark symptom. [2] |
| Tea-coloured / dark urine | Conjugated (water-soluble) bilirubin cannot drain into the gut → accumulates in blood → filtered by kidneys → excreted in urine, giving it a dark tea/cola colour [5] [8] |
| Pale / clay-coloured stool (acholic stool) | Bilirubin cannot reach the gut → no conversion to stercobilin (which normally gives stool its brown colour) → pale, putty-like stool [5] [8] |
| Steatorrhoea | Bile salts cannot reach the duodenum → impaired fat emulsification → fat malabsorption → floating, foul-smelling, difficult-to-flush stool [2] |
| Pruritus | Bile salts accumulate in the blood and deposit in the skin → stimulate sensory nerve endings. Can be intensely distressing and precede visible jaundice. [8] |
| Weight loss / anorexia (constitutional symptoms) | Cancer cachexia (cytokine-mediated — TNF-α, IL-6) + fat malabsorption + anorexia [5] [7] |
| Epigastric/RUQ pain | Late feature in MBO (unlike gallstone disease). When present: tumour invasion of retroperitoneal structures (especially in pancreatic body/tail CA — severe epigastric pain radiating to the back from retroperitoneal/coeliac plexus infiltration) [7] [14] |
| New-onset diabetes mellitus | Specific to pancreatic cancer — destruction of islet cells by tumour or tumour-associated insulin resistance. New-onset DM in elderly can be early manifestation of occult pancreatic CA [7] |
| Nausea and vomiting | If tumour also causes duodenal/gastric outlet obstruction (especially CA head of pancreas — distended stomach due to duodenal obstruction by tumour which obstructs the bile duct as well) [11] |
| Fever/rigors | If secondary cholangitis develops (biliary sepsis). Note: isolated MBO without infection = no fever. Fever suggests superimposed infection [13] |
| Symptoms of pancreatic insufficiency | Steatorrhoea, maldigestion, malabsorption — if pancreatic duct also obstructed (double duct sign) [14] |
| Trousseau syndrome | Pancreatic cancer: hypercoagulable state → migratory superficial thrombophlebitis (a paraneoplastic phenomenon). "Trousseau" = Greek physician who described this and ironically died of it [14] |
The Classic Exam Presentation
A 65-year-old man presents with progressive yellowing of the eyes for 3 weeks, dark urine, pale stools, 5 kg weight loss, and no pain. On examination, the gallbladder is palpable. → This is MBO (likely CA head of pancreas) until proven otherwise.
| Sign | Pathophysiological Basis |
|---|---|
| Jaundice (yellow sclera and skin) | Bilirubin > 50 μmol/L becomes clinically detectable [2]. Sclera affected first because bilirubin has high affinity for elastin (sclera is rich in elastic fibres). |
| Palpable, non-tender gallbladder (Courvoisier's sign) | Courvoisier's Law: "In painless jaundice, if the gallbladder is palpable, it is unlikely to be due to gallstones" → points towards malignant biliary obstruction [5] [12]. Why? Gallstones develop chronically → repeated cholecystitis → fibrosed, contracted gallbladder → CANNOT distend. Malignant obstruction develops over weeks-months in a previously normal, compliant gallbladder → back-pressure → GB distends. |
| Hepatomegaly | Hepatomegaly secondary to biliary obstruction (congested, cholestatic liver) OR hepatomegaly due to metastases or HCC [11] |
| Epigastric mass | Could be: distended GB, hepatomegaly, enlarged lymph nodes at porta hepatis/coeliac axis, or distended stomach (from duodenal obstruction) [11] |
| Scratch marks (excoriation) | Secondary to pruritus from bile salt deposition in skin |
| Cachexia / muscle wasting | Cancer cachexia + malnutrition |
| Ascites | Peritoneal metastases (carcinomatosis) or portal hypertension from hepatic/portal vein invasion |
| Bruising / petechiae | Coagulopathy from vitamin K deficiency |
| Signs of metastasis | Virchow's node (left supraclavicular — "Troisier's sign"), Sister Mary Joseph nodule (umbilical metastasis), Blumer's shelf (palpable mass on rectal exam from pelvic peritoneal metastasis), Krukenberg tumour (ovarian metastasis), hepatomegaly (liver metastasis) |
| Succussion splash | If gastric outlet obstruction present (distended stomach with retained fluid) [15] |
Courvoisier's Law — Know the Exceptions!
Exceptions to Courvoisier's Law (palpable GB WITH gallstone disease) [5] [12]:
- Double impaction: One stone at CBD causing jaundice + another at cystic duct causing GB distension (mucocele in a fibrotic GB)
- Mirizzi syndrome: Stone impacted at Hartmann's pouch/cystic duct → extrinsic compression of CHD (jaundice + palpable GB — because the essential pathology is CHD compression, NOT chronic cholecystitis)
- Recurrent pyogenic cholangitis (RPC): Essential pathology is in bile duct, NOT gallbladder → CBD obstruction by intrahepatic stones → jaundice WITHOUT chronic cholecystitis → GB not fibrosed → can distend [5]
| Feature | Medical (Pre-hepatic/Hepatic) | Surgical (Obstructive) |
|---|---|---|
| Urine colour | Normal | Tea-coloured |
| Stool colour | Normal | Pale-coloured |
| Steatorrhoea | Absent | Present (floating, foul-smelling, difficult to flush) |
| Pruritus | Uncommon (except intrahepatic cholestasis) | Common and prominent |
| Associated features | Pre-hepatic: palpitations, dizziness (haemolysis). Hepatic: fever, RUQ pain, N/V (hepatitis) | Progressive jaundice, weight loss, palpable GB |
| Feature | Gallstone | Tumour |
|---|---|---|
| Pain | Colicky, episodic | Painless (or constant dull ache if advanced) |
| Jaundice course | Fluctuating (stone acts as ball-valve) | Progressive |
| Fever | Common (cholangitis) | Uncommon unless superimposed cholangitis |
| GB palpable | Usually NOT (fibrosed) | Often YES (Courvoisier's) |
| Weight loss | Minimal | Significant |
| Age | Any | Typically elderly |
9. Specific Clinical Features by Underlying Malignancy
- Painless progressive obstructive jaundice (tumour at head — 70%)
- Severe epigastric pain radiating to the back (tumour at body/tail — retroperitoneal infiltration of coeliac plexus)
- Constitutional symptoms (weight loss, anorexia)
- Symptoms of pancreatic insufficiency: steatorrhoea, maldigestion, malabsorption, new-onset DM
- Acute pancreatitis / gastric outlet obstruction (GOO)
- Paraneoplastic manifestations: Trousseau syndrome (migratory superficial thrombophlebitis), paraneoplastic pemphigoid [14]
- Double duct sign on imaging — dilated pancreatic duct + dilated CBD (both ducts compressed by pancreatic head mass)
- Sites of metastasis: liver, peritoneum, lung, bone
- Jaundice: ONLY in extrahepatic (perihilar/distal) cholangiocarcinoma
- Intrahepatic cholangiocarcinoma will NOT cause jaundice (bilirubin reabsorbed and re-excreted through unaffected liver) — instead presents as a liver mass
- Dark urine and pale stools (extrahepatic cholestasis)
- Pruritus, RUQ pain, fever (if cholangitis), weight loss
- Haemobilia (UGIB from biliary tree) — uncommon [3]
- Hepatomegaly (intrahepatic type)
- Palpable GB (Courvoisier's law — if distal tumour) [3]
- Early stage: often asymptomatic or mimics cholelithiasis/cholecystitis (biliary colic, RUQ pain)
- Late stage: obstructive jaundice, palpable mass, constitutional symptoms
- Metastasis: direct extension into liver (segments IV & V), peritoneal seeding [10]
- Ascites, dyspnoea/cough/haemoptysis (distant metastases) [5]
- RUQ pain ± right shoulder pain (Glisson's capsule distension)
- Hepatomegaly
- Obstructive jaundice: NOT common — occurs only when mass near confluence or by tumour fragments/direct infiltration of CBD
- Deranged LFT in cirrhotic patients: encephalopathy, coagulopathy, portal HT (ascites, oedema, variceal bleeding)
- Paraneoplastic syndromes: erythrocytosis (EPO), hypoglycaemia (IGF-2), hypercalcaemia (PTHrP)
- Ruptured HCC (haemoperitoneum — surgical emergency)
10. Important Concepts — Tying It Together
The reason MBO causes painless jaundice is fundamentally about the speed of obstruction:
- Gallstones cause acute, sudden obstruction → rapid biliary distension → pain (visceral pain from stretching of bile duct wall)
- Malignant tumours grow slowly → gradual obstruction → bile ducts have time to dilate and accommodate → no acute pain
- The gallbladder similarly has time to distend gradually → painless, palpable GB
The ampulla of Vater is the narrowest point of the entire biliary/pancreatic drainage system. Even a tiny tumour here will cause obstruction → early jaundice → early presentation → earlier diagnosis → better stage at diagnosis → better prognosis [5].
In contrast, pancreatic body/tail tumours have no nearby duct to obstruct early, so they present late with pain and metastases.
The three main causes of death in MBO are:
- Biliary sepsis
- Cancer cachexia
- Liver failure
High Yield Summary
-
Definition: MBO = obstruction of the biliary tract by cancer growth within or around it. Painless progressive obstructive jaundice in elderly = MBO until proven otherwise.
-
Key Causes (from lecture slides): CA duodenum, periampullary CA, CA pancreas, lymphoma, CA gallbladder (cystic duct LN, direct CBD infiltration, tumour fragments), cholangiocarcinoma at hilum (Klatskin tumour), HCC (direct infiltration, compression, tumour fragments in CBD).
-
Anatomy: Know the biliary tree from intrahepatic ducts → CHD → CBD → Ampulla of Vater. Level of obstruction determines clinical features and imaging findings.
-
Pathophysiology of obstruction: Bile stasis → jaundice, dark urine, pale stool, steatorrhoea, fat-soluble vitamin malabsorption (especially Vitamin K → coagulopathy), loss of biliary barrier → cholangitis/sepsis, impaired immunity, poor wound healing, renal vulnerability.
-
Causes of mortality in MBO: biliary sepsis, cancer cachexia, liver failure.
-
Courvoisier's Law: In painless jaundice + palpable GB → unlikely gallstones → think MBO. Exceptions: double impaction, Mirizzi syndrome, RPC.
-
Clinical differentiation: Stone = painful, fluctuating jaundice, fever. Tumour = painless, progressive jaundice, weight loss, palpable GB.
-
Bismuth-Corlette: Classification of perihilar cholangiocarcinoma (Types I–IV) — essential for surgical planning.
-
Jaundice + epigastric mass: Hepatomegaly (obstruction/metastases/HCC), porta hepatis lymphadenopathy, distended stomach from duodenal obstruction.
-
MBO patients are high-risk surgical candidates due to coagulopathy, immunosuppression, poor wound healing, renal vulnerability, malnutrition, and liver dysfunction.
Active Recall - Malignant Biliary Obstruction
[1] Lecture slides: WCS 056 - Painless jaundice and epigastric mass - by Prof R Poon.ppt (1).pdf, p2–3 [2] Senior notes: maxim.md, Section 5.3 Obstructive jaundice [3] Senior notes: maxim.md, Cholangiocarcinoma section [4] Senior notes: maxim.md, Hepatocellular carcinoma section [5] Senior notes: felixlai.md, Malignant biliary obstruction section (pp. 498–505) [6] Senior notes: maxim.md, Recurrent pyogenic cholangitis section [7] Senior notes: felixlai.md, Pancreatic cancer section (p. 591) [8] Senior notes: felixlai.md, Cholangiocarcinoma clinical manifestation section (p. 548) [9] Lecture slides: Malignant biliary obstruction.pdf, p29 [10] Senior notes: maxim.md, CA gallbladder section [11] Lecture slides: WCS 056 - Painless jaundice and epigastric mass - by Prof R Poon.ppt (1).pdf, p32 [12] Senior notes: maxim.md, Courvoisier's Law note (p. 130); felixlai.md, Courvoisier's Law (p. 567) [13] Senior notes: felixlai.md, Acute cholangitis section (p. 520) [14] Senior notes: maxim.md, Pancreatic carcinoma section (p. 146) [15] Senior notes: maxim.md, Gastric outlet obstruction section (p. 130)
Differential Diagnosis of Malignant Biliary Obstruction
The differential diagnosis of MBO is really about answering a series of nested clinical questions. When a patient walks in with jaundice, you don't jump straight to "cancer" — you systematically narrow down: Is this jaundice? → Is it obstructive? → Is the obstruction benign or malignant? → What is the specific malignant cause? Let's work through this framework from first principles.
Before you can diagnose MBO, you must first establish that the jaundice is obstructive (post-hepatic/surgical) rather than pre-hepatic or hepatic (medical). This is fundamental because the management pathways are completely different — medical jaundice goes to the gastroenterologist/physician; obstructive jaundice goes to the surgeon.
| Category | Mechanism | Urine | Stool | Key Features |
|---|---|---|---|---|
| Pre-hepatic | Excess bilirubin production (unconjugated) — overwhelms hepatic conjugation capacity | Normal or slightly dark (urobilinogen ↑) | Normal or dark (↑ stercobilin) | Haemolysis (palpitations, dizziness, anaemia, splenomegaly), Gilbert's syndrome |
| Hepatic | Hepatocyte dysfunction — impaired uptake, conjugation, or excretion of bilirubin | May be dark | May be normal or slightly pale | Hepatitis (fever, RUQ pain, N/V, transaminases ↑↑), decompensated CLD (ascites, spider naevi, encephalopathy), drugs |
| Post-hepatic (Obstructive) | Mechanical obstruction of bile flow — conjugated bilirubin cannot reach gut | Tea-coloured | Pale-coloured | Steatorrhoea, pruritus, cholestatic LFT pattern (ALP/GGT ↑↑), ± palpable GB [2] |
Why does this distinction matter? Because conjugated bilirubin is water-soluble — it is filtered by the kidneys and appears in urine (dark/tea-coloured). Unconjugated bilirubin is albumin-bound and NOT filtered by the kidneys — so urine stays normal in pre-hepatic jaundice. And if bile can't reach the gut, there's no stercobilin production → pale stool. These are bedside clues you can elicit in 30 seconds. [2]
History Tip
When asking about tea-coloured urine, always exclude non-pathological causes: no recent intake of rifampicin, Pyridium (phenazopyridine), or beetroot — these can all turn urine dark/red and mislead you. [2]
Once you've established the jaundice is obstructive, the next question is: what is causing the obstruction? A clean way to think about this is by the anatomical relationship of the pathology to the bile duct wall [2]:
Differential diagnosis of obstructive jaundice: [2]
- Intraluminal: gallstone (choledocholithiasis, acute cholangitis), RPC
- Mural: cholangiocarcinoma, PSC
- Extramural: CA head of pancreas, lymphadenopathy, gallstone (Mirizzi's syndrome)
| Relationship to Duct Wall | Pathology | Mechanism of Obstruction |
|---|---|---|
| Intraluminal | Choledocholithiasis (CBD stones) | Stone physically blocks the duct lumen — "ball-valve" effect causes fluctuating jaundice |
| Acute cholangitis | Stone + superimposed infection (obstruction + bacteria = cholangitis) [13] | |
| RPC | Intrahepatic pigment stones + strictures → recurrent cholangitis [6] | |
| Blood clot / haemobilia | Post-procedural or tumour erosion into a vessel → clot in bile duct | |
| Parasites | Ascaris lumbricoides, Clonorchis sinensis physically inhabit the ducts | |
| Mural (intrinsic) | Cholangiocarcinoma | Tumour arises FROM the bile duct epithelium → intrinsic narrowing/obstruction [3] |
| PSC | Chronic inflammation → fibrosis → stricturing of bile ducts [16] | |
| PBC | T-cell attack on small intralobular bile ducts → intrahepatic cholestasis [17] | |
| Benign strictures | Iatrogenic (post-surgical), TB, autoimmune → scarring narrows lumen [5] | |
| Extramural (extrinsic) | CA head of pancreas | Pancreatic head wraps around distal CBD → compression [7] [14] |
| CA gallbladder | Spread to cystic duct LN, direct infiltration of CBD [1] [5] | |
| Lymphadenopathy | Porta hepatis / coeliac nodes compress CBD from outside | |
| Mirizzi syndrome | Stone impacted in Hartmann's pouch compresses CHD externally [12] | |
| Chronic pancreatitis / pancreatic cysts | Inflammatory mass or cyst compresses distal CBD | |
| Choledochal cysts | Congenital dilatation → stasis ± compression |
This is the crux of the matter. The clinical approach is: Is this stone disease (benign) or cancer (malignant)? The distinction drives urgency and management.
| Feature | Benign (Stone Disease) | Malignant (MBO) |
|---|---|---|
| Pain | Colicky, episodic (biliary colic — visceral pain from acute duct distension by stone) | Painless (gradual tumour growth → slow obstruction → no acute distension) |
| Jaundice course | Fluctuating (stone acts as ball-valve — moves in and out of ampulla) | Progressive (tumour relentlessly grows — obstruction only worsens) |
| Fever | Common — cholangitis (Charcot's triad: fever, RUQ pain, jaundice) [13] | Uncommon unless superimposed cholangitis from stasis |
| GB palpable | Usually NOT palpable — chronic cholecystitis → fibrosed, contracted GB | Often palpable — Courvoisier's sign (previously normal GB distends from back-pressure) [5] [12] |
| Weight loss | Minimal | Significant (cancer cachexia + fat malabsorption) |
| Age | Any age (peak 40–60) | Typically elderly ( > 60) |
| History | Known gallstones, previous episodes of biliary colic/cholecystitis | New-onset DM (pancreatic CA), smoking history, PSC/RPC |
| LFT pattern | Cholestatic (↑ ALP, GGT, conjugated bilirubin) — may fluctuate | Cholestatic — persistently rising |
Courvoisier's Law — The Exam Classic
"In painless jaundice, if the gallbladder is palpable, it is unlikely to be due to gallstones" → points towards MBO [5] [12]
Why? Gallstones develop over years → repeated bouts of cholecystitis → GB wall becomes fibrosed and contracted → even if CBD is obstructed, the GB cannot distend. In MBO, the GB was previously normal and compliant → back-pressure from distal obstruction → GB distends.
Exceptions (palpable GB WITH stones) [5] [12]:
- Double impaction — stone at CBD (jaundice) + stone at cystic duct (GB distension via mucocele)
- Mirizzi syndrome — stone at Hartmann's pouch compresses CHD externally; the GB itself may not be chronically inflamed
- RPC — pathology is in the intrahepatic ducts, NOT in the GB; GB is not fibrosed and can distend
This is clinically extremely useful. When you get imaging back (USG, CT, MRCP), you determine which parts of the biliary tree are dilated and this tells you WHERE the obstruction is. Then you generate a focused differential for that level [5]:
| Level of Obstruction | Imaging Finding | Malignant Causes | Benign Causes |
|---|---|---|---|
| Hilum | Dilated intrahepatic ducts; CBD may be normal; GB usually NOT distended (obstruction ABOVE cystic duct junction) | Klatskin's tumour (cholangioCA at hilum) [1], CA gallbladder, HCC, porta lymphadenopathy, lymphoma [1] | Mirizzi syndrome, PSC, RPC |
| Mid-CBD | Dilated intrahepatic + proximal extrahepatic ducts; GB variably distended | CA CBD, CA head of pancreas [1], lymphadenopathy | — |
| Distal CBD | Dilated intrahepatic + extrahepatic ducts; GB distended (Courvoisier's sign) | Periampullary carcinoma (CA head of pancreas, CA ampulla, CA distal CBD, CA duodenum) [1] [5] | Choledochal cysts, pancreatic cysts, chronic pancreatitis, benign strictures |
Why does the GB distend only in distal obstruction? Because the cystic duct enters the CBD approximately at the junction of the upper and middle thirds. If the obstruction is below the cystic duct junction (distal CBD), back-pressure transmits into the gallbladder via the cystic duct → GB distends. If the obstruction is above the cystic duct junction (hilum), the cystic duct is still patent and drains into a non-obstructed distal CBD → no GB distension. [5]
A special note on hilar obstruction: Obstruction of just ONE hepatic duct (e.g., only the right) will NOT cause jaundice because the contralateral lobe excretes bilirubin normally through its patent duct. The Klatskin tumour causes jaundice because it sits at the confluence and blocks BOTH ducts. [5] [8]
5. The Specific Malignant Causes — Differentiating Between Them
Once you suspect MBO, the next step is: which cancer is it? This matters because treatment differs.
The lecture slide specifically lists:
Carcinoma of duodenum, periampullary carcinoma, carcinoma of pancreas, lymphoma, carcinoma of gallbladder (cystic duct LN, direct infiltration of CBD, tumour fragments), cholangiocarcinoma at hilum (Klatskin tumour), HCC (direct infiltration, compression, tumour fragments in CBD) [1]
| Malignancy | Key Differentiating Features | Age/Sex | Tumour Marker Clues |
|---|---|---|---|
| CA head of pancreas | Painless progressive jaundice + severe epigastric pain radiating to back (body/tail) + new-onset DM + weight loss; double duct sign on CT [14] | Elderly, male | CA 19-9 (↑ in 72–79% but not specific) [18] |
| CA ampulla of Vater | Earliest presentation with jaundice (narrow ampulla); best prognosis among periampullary CAs [5]; intermittent jaundice possible (tumour can intermittently bleed and slough → temporarily relieving obstruction) | Elderly | CA 19-9, CEA |
| CA duodenum | May present with duodenal obstruction (GOO) + jaundice; rare | Elderly | CEA |
| CA distal CBD | Pure obstructive jaundice without pancreatic insufficiency features | Elderly | CA 19-9, CEA |
| Cholangiocarcinoma / Klatskin tumour | Hilar obstruction → intrahepatic duct dilatation only; intrahepatic CC does NOT cause jaundice [8]; slow growth, perineural invasion [8]; prone to cholangitis [3] | Elderly, M > F slightly | CA 19-9 (↑ in 80%), CEA, AFP (to differentiate from HCC) [3] |
| CA gallbladder | History mimics cholecystitis/gallstones (95% have co-existing stones); late: obstructive jaundice, palpable mass; direct extension into liver segments IV & V [10]; female predominance [10] | Elderly, female | CA 19-9 |
| HCC | Known CLD/cirrhosis/HBV carrier in HK; hepatomegaly; stigmata of CLD; obstructive jaundice NOT common — occurs only near confluence or by tumour fragments in CBD [4] [5]; AFP elevated in 70–90% [18] | Elderly (50–70), male (HBV HK) | AFP (70–90%) [18] |
| Lymphoma [1] | B symptoms (fever, night sweats, weight loss); lymphadenopathy elsewhere; younger age possible | Variable | LDH ↑, β2-microglobulin |
| Secondary lymphadenopathy | Known primary (CRC, gastric CA); CA stomach with metastatic LN in porta hepatis [11] | Variable | CEA (if CRC/gastric) |
Tumour Markers — Useful but NOT Diagnostic
Tumour markers such as AFP, CA 19-9, and CEA are often elevated but are NOT diagnostically useful since they lack sensitivity and specificity. [5] [7]
- CA 19-9: Raised in pancreatic CA (72–79%), biliary CA (67–73%), gastric CA (42–62%), CRC (19–41%), and also in benign biliary diseases (cholangitis, cholelithiasis) [18]
- CEA: Raised in CRC (30–70%), but also in smoking, liver disease, pancreatitis [18]
- AFP: Primarily for HCC (70–90%), but also raised in hepatitis, cirrhosis, biliary obstruction itself [18]
- Absence of elevated tumour markers does NOT exclude underlying malignancy [5]
- Serial assay after resection may aid in detection of persistent or recurrent disease [5]
The senior notes highlight that the differential diagnosis for pancreatic cancer is broad and should be based upon whether the mass is cystic or solid on imaging [7]:
| Solid mass | Cystic mass |
|---|---|
| Pancreatic ductal adenocarcinoma (most common) | IPMN (intraductal papillary mucinous neoplasm) |
| Chronic pancreatitis (focal) | Mucinous cystic neoplasm (MCN) |
| Pancreatic neuroendocrine tumour | Serous cystadenoma (benign) |
| Metastasis to pancreas (RCC most common, also lung, breast) [14] | Pseudocyst (post-pancreatitis) |
| Lymphoma | Solid pseudopapillary neoplasm |
| Autoimmune pancreatitis (IgG4-related) |
This is a specific clinical scenario highlighted by the lecture slides [11]. When both jaundice AND an epigastric mass are present, consider:
Pathology producing jaundice and epigastric mass: [11]
- Hepatomegaly secondary to biliary obstruction
- Hepatomegaly due to metastases or HCC
- Lymph node metastases to the coeliac axis or porta hepatis
- Carcinoma of stomach with metastatic lymph node in the porta hepatis
- Distended stomach due to duodenal obstruction by tumour which obstructs the bile duct as well
Why do these all cause BOTH jaundice AND a mass?
| Pathology | Why Jaundice? | Why Mass? |
|---|---|---|
| Hepatomegaly from biliary obstruction | Distal bile duct obstruction → cholestasis | Congested, swollen liver palpable below costal margin |
| Hepatomegaly from metastases/HCC | Tumour near hilum compresses bile ducts, OR massive liver infiltration → hepatocyte dysfunction | Enlarged liver riddled with tumour nodules — often irregular, hard, nodular surface |
| Coeliac/porta hepatis LN metastases | Enlarged nodes compress CBD/CHD | Palpable lymph node mass in epigastrium |
| CA stomach with porta hepatis LN [11] | Metastatic lymph nodes compress the bile duct | Primary gastric tumour ± lymph node mass |
| Distended stomach from duodenal obstruction | Tumour causing GOO also compresses bile duct (e.g., CA head of pancreas invading both duodenum and CBD) | Distended, fluid-filled stomach — succussion splash on examination [15] |
7. Specific Benign Mimics of MBO That Must Be Excluded
Charcot's triad (50–70%): Fever, RUQ pain, jaundice Reynold's pentad ( < 10%): above + shock + altered mental status [13]
- Usually caused by choledocholithiasis (most common), but MBO itself can cause cholangitis (stasis + bacteria)
- The presence of fever and pain distinguishes cholangitis from "pure" MBO. However, MBO can be complicated by cholangitis — so cholangitis doesn't exclude MBO, it just means there's superimposed infection.
- CHD obstruction caused by extrinsic compression from an impacted stone in Hartmann's pouch/cystic duct [12]
- Can present as jaundice with palpable GB — an exception to Courvoisier's Law [12]
- Important to recognise because it can mimic cholangiocarcinoma on imaging — CT with contrast needed to rule out malignant causes (e.g., porta hepatis LN) [12]
- Chronic progressive inflammation → fibrosis → "beading" of bile ducts on cholangiography
- Strong association with ulcerative colitis [16]
- Can itself be a risk factor for cholangiocarcinoma — so PSC and cholangiocarcinoma can coexist, making differentiation extremely difficult
- IgG4-associated cholangitis must be distinguished from PSC (elderly male, responds to steroids) [16]
- T-lymphocyte attack on small intralobular bile ducts → intrahepatic cholestasis
- Extreme female predominance (90–95%), middle-aged [17]
- Anti-mitochondrial antibody (AMA) positive
- Does NOT cause extrahepatic duct dilatation — this is a key imaging distinction from MBO
- Congenital dilatation of intra/extrahepatic biliary system
- Most diagnosed before age 10 (60%)
- Classic triad: RUQ mass + pain + jaundice + fever
- Important because they are a risk factor for cholangiocarcinoma — can undergo malignant transformation
- Infiltration of biliary system with IgG4-positive plasma cells; predominantly elderly male [16]
- Can mimic cholangiocarcinoma or PSC on imaging
- Serum IgG4 elevated; responds dramatically to corticosteroids (unlike cholangiocarcinoma)
- Must be distinguished from cholangiocarcinoma before committing to major surgery [8]
- IgG4-related disease affecting the pancreas → can cause a pancreatic head mass mimicking pancreatic cancer
- "Sausage-shaped" pancreas on CT; elevated IgG4; responds to steroids
- Critical to differentiate because treatment is medical (steroids), not surgical (Whipple's)
The senior notes specifically list the DDx for cholangiocarcinoma — which is essentially the DDx for any patient presenting with hilar or proximal biliary obstruction:
- Choledocholithiasis — stones cause intraluminal obstruction; fluctuating jaundice, pain, fever
- Viral hepatitis — hepatic cause; transaminases ↑↑; no duct dilatation on imaging
- HCC — AFP elevated; known CLD/HBV; usually hepatomegaly rather than obstructive jaundice
- Pancreatic cancer — distal CBD obstruction; double duct sign; CA 19-9
- Cancer of the ampulla of Vater — earliest jaundice; visible on OGD at ampulla
- PSC — beaded bile ducts on cholangiography; associated with UC; chronic course
- PBC — AMA positive; female; small duct cholestasis; no extrahepatic dilatation
| Diagnosis | Pain | Jaundice | Fever | GB | Weight Loss | Key Investigation Finding |
|---|---|---|---|---|---|---|
| CBD stone | Colicky | Fluctuating | ± (cholangitis) | Not palpable | Minimal | Stone on USG/MRCP |
| CA head pancreas | Late, radiates to back | Progressive, painless | Rare | Palpable | Marked | Hypoattenuating mass, double duct sign on CT |
| Klatskin tumour | Dull RUQ | Progressive, painless | ± cholangitis | Not palpable (hilar) | Moderate | Intrahepatic dilatation only; MRCP shows hilar stricture |
| CA gallbladder | RUQ (mimics cholecystitis) | Late | Rare | May be mass | Late | GB mass on USG/CT; segments IV/V involvement |
| HCC | RUQ | Uncommon | Rare | Not palpable | Variable | AFP ↑; cirrhotic liver; arterial enhancement on CT |
| CA ampulla | Minimal | Progressive (may intermittently resolve) | Rare | Palpable | Moderate | Visible on OGD; periampullary mass |
| Mirizzi syndrome | RUQ (cholecystitis-like) | Variable | ± cholangitis | Palpable (exception) | Minimal | Stone at GB neck compressing CHD on MRCP |
| PSC | Dull RUQ | Chronic, progressive | ± cholangitis | Not palpable | Late | Beaded ducts on MRCP; p-ANCA +; UC history |
| Cholangitis | RUQ | Yes | Yes (Charcot's) | Not palpable | Minimal | Dilated duct + stone; blood culture + |
High Yield Summary
-
Systematic approach: Jaundice → Pre-hepatic/Hepatic/Obstructive (urine + stool colour) → If obstructive: Benign (stone) vs Malignant (tumour) → Level of obstruction (hilar/mid/distal) → Specific cause.
-
Differential of obstructive jaundice: Intraluminal (stone, RPC), Mural (cholangiocarcinoma, PSC), Extramural (CA head pancreas, lymphadenopathy, Mirizzi's) [2].
-
Stone vs Tumour: Stone = painful, fluctuating jaundice, fever, GB NOT palpable. Tumour = painless, progressive jaundice, weight loss, GB palpable (Courvoisier's).
-
Malignant causes from lecture: CA duodenum, periampullary CA, CA pancreas, lymphoma, CA gallbladder, cholangioCA/Klatskin tumour, HCC [1].
-
Level of obstruction on imaging: Hilar (intrahepatic dilatation only → Klatskin, CA GB, HCC), Mid-CBD (CA CBD, CA pancreas head, LN), Distal (periampullary CA → GB distended).
-
Jaundice + epigastric mass: Hepatomegaly (obstruction/metastases/HCC), porta hepatis LN metastases, CA stomach with porta LN, distended stomach from duodenal obstruction [11].
-
Tumour markers (CA 19-9, CEA, AFP) are neither sensitive nor specific — absence does NOT exclude malignancy; presence does NOT confirm it [5] [18].
-
Must-exclude benign mimics: Mirizzi syndrome, PSC, IgG4-related cholangitis, autoimmune pancreatitis, choledochal cysts — all can mimic MBO on imaging.
Active Recall - Differential Diagnosis of MBO
References
[1] Lecture slides: WCS 056 - Painless jaundice and epigastric mass - by Prof R Poon.ppt (1).pdf, p23 [2] Senior notes: maxim.md, Section 5.3 Obstructive jaundice [3] Senior notes: maxim.md, Cholangiocarcinoma section [4] Senior notes: maxim.md, Hepatocellular carcinoma section [5] Senior notes: felixlai.md, Malignant biliary obstruction section (pp. 498–502) [6] Senior notes: maxim.md, Recurrent pyogenic cholangitis section [7] Senior notes: felixlai.md, Pancreatic cancer section (p. 591) [8] Senior notes: felixlai.md, Cholangiocarcinoma clinical manifestation and DDx (p. 548) [10] Senior notes: maxim.md, CA gallbladder section [11] Lecture slides: WCS 056 - Painless jaundice and epigastric mass - by Prof R Poon.ppt (1).pdf, p32 [12] Senior notes: maxim.md, Mirizzi syndrome section; felixlai.md, Courvoisier's Law [13] Senior notes: felixlai.md, Acute cholangitis section (p. 520); maxim.md, Acute cholangitis section [14] Senior notes: maxim.md, Pancreatic carcinoma section (p. 146) [15] Senior notes: maxim.md, Gastric outlet obstruction section [16] Senior notes: felixlai.md, Primary sclerosing cholangitis section [17] Senior notes: felixlai.md, Primary biliary cholangitis section [18] Lecture slides: Malignant biliary obstruction.pdf, p8 [19] Senior notes: maxim.md, Choledochal cyst section
Diagnosis of Malignant Biliary Obstruction — Criteria, Algorithm & Investigations
There is no single "diagnostic criterion" for MBO the way there is for, say, acute cholangitis (Tokyo Guidelines) or PBC (AMA + ALP + histology). MBO is a clinical-radiological diagnosis — you put together the clinical picture (painless progressive jaundice, Courvoisier's sign) with biochemistry (cholestatic LFT) and imaging (dilated ducts + mass) to arrive at a diagnosis and then characterise the underlying malignancy.
The lecture frames the management approach in four sequential steps [20]:
Management of MBO: [20]
- Establish diagnosis
- Delineate level and cause of obstruction
- Treat suppurative cholangitis
- Definitive treatment
And the learning objectives explicitly state [1]:
Imagings for jaundice and epigastric mass [1]
So the diagnostic workup is systematically: Clinical assessment → Bloods → Imaging (anatomical → cholangiographic → tissue) → Staging. Let's go through each layer.
2. Physical Examination — What to Look For and Why
Physical examination in MBO is not just "ticking boxes" — each finding tells you something about the disease and its stage.
| Finding | What It Tells You |
|---|---|
| Jaundice | Bilirubin > 50 μmol/L; sclera first (elastin affinity) → skin |
| Cachexia | Advanced malignancy; cancer cachexia (TNF-α, IL-6) + fat malabsorption |
| Scratch marks (excoriation) | Pruritus from bile salt deposition in skin — indicates significant cholestasis [5] |
| Lymphadenopathy | Check left supraclavicular (Virchow's node/Troisier's sign — thoracic duct drainage from abdominal malignancy), cervical, axillary |
| Finding | Significance |
|---|---|
| Courvoisier's sign (palpable GB) | ALWAYS look for a palpable gallbladder in MBO [5]. Distal obstruction in previously normal GB. |
| Hepatomegaly | Biliary congestion, metastatic deposits, or HCC. Irregular surface = metastatic deposits or HCC [5] |
| Stigmata of chronic liver disease | Spider naevi, palmar erythema, gynaecomastia → suggests underlying cirrhosis (HCC more likely) |
| Signs of inoperability [5] | These are critical because finding them on examination means the cancer is advanced/metastatic and curative resection is not possible: |
Signs of inoperability [5]:
- Irregular surface hepatomegaly — suggests metastatic liver deposits; irregular nodular surface
- Troisier's sign (Virchow's node) — left supraclavicular lymph node; indicates distant lymphatic spread via thoracic duct
- Blumer's shelf — palpable mass on digital rectal exam; peritoneal metastasis seeding to the rectovesical/rectouterine pouch (most dependent peritoneal recess)
- Sister Mary Joseph nodules — umbilical nodule; peritoneal metastasis tracking along the obliterated umbilical vein (ligamentum teres)
- Ascites — peritoneal carcinomatosis (malignant ascites)
Why These Signs Mean Inoperability
Each sign represents distant metastatic spread: Virchow's node = distant lymphatic spread, Blumer's shelf and Sister Mary Joseph nodule = peritoneal seeding, irregular hepatomegaly = liver metastases, ascites = carcinomatosis. Any of these means the cancer has spread beyond what a surgeon can remove with curative intent. The operation would carry all the morbidity but provide no survival benefit.
3. Biochemical Investigations
| Test | Expected Finding in MBO | Why Order It? (Pathophysiological Basis) |
|---|---|---|
| CBC with differentials | Pancytopenia (if underlying cirrhosis + hypersplenism); leukocytosis (if biliary sepsis); thrombocytopenia (important for planning invasive procedures like ERCP) [5] | Anaemia may indicate chronic disease or GI blood loss. Leukocytosis flags superimposed cholangitis. Platelets must be checked before ANY biliary instrumentation. |
| Clotting profile (PT/INR) | Prolonged PT/INR — coagulopathy due to Vitamin K deficiency from decreased absorption of fat-soluble vitamins due to obstructive jaundice [5] | Must be corrected with parenteral Vitamin K before any invasive procedure or surgery. If PT does NOT correct with Vitamin K → suspect hepatocellular dysfunction (worse prognosis). |
| LFT | ↑ Bilirubin (conjugated/direct), ↑ ALP and GGT (cholestatic pattern) [5] | The cholestatic pattern (ALP/GGT ↑↑ > AST/ALT) distinguishes obstructive from hepatocellular jaundice. ALP is produced by bile duct epithelium in response to obstruction. GGT confirms the excess ALP is of hepatobiliary origin (not bone). [8] |
| HBV and HCV serology | May be positive | Screen for viral hepatitis — if positive, raises suspicion for HCC as the cause of MBO. Also important for perioperative planning. [5] |
| RFT (Renal function) | May show rising creatinine | Obstructive jaundice → cholemic nephrosis / hepatorenal vulnerability. Baseline essential before contrast imaging or surgery. |
| Serum glucose | May show new-onset hyperglycaemia | New-onset DM can be an early manifestation of occult pancreatic cancer [7]. Also important for perioperative glucose control. |
| Serum amylase/lipase | May be elevated | If pancreatic duct also obstructed → pancreatitis; or direct pancreatic parenchymal involvement [14] |
| Serum albumin | May be low | Marker of nutritional status and hepatic synthetic function. Low albumin = poor prognosis, higher operative risk. [7] |
| Serum IgG4 | May be elevated | Evaluate for the possibility of IgG4-related sclerosing cholangitis [8] — this is a critical mimic of cholangiocarcinoma that responds to steroids instead of surgery |
| Blood culture | May be positive | Must order if fever/cholangitis suspected [13] — identify organism and guide antibiotic therapy |
This is an area where students often get confused. Let's be crystal clear:
Tumour markers such as AFP, CA 19-9, and CEA are NOT very useful for MBO as a screening tool and are not included in the initial testing. [5] Common tumour markers are neither sensitive nor specific for periampullary tumours. [5] Absence of an elevated tumour marker does not exclude underlying malignancy. [5]
The lecture slide provides a detailed marker table [18]:
| Marker | Upper Normal | Raised In Malignancy | Sensitivity | Non-malignant Causes of Elevation |
|---|---|---|---|---|
| AFP | 10 ng/mL | HCC (70–90%); cholangioCA (10%) | Moderate for HCC | Hepatitis, cirrhosis, biliary tract obstruction, ALD [18] |
| CEA | 5 ng/mL | CRC (30–70%); gastric, pancreatic, lung, breast CA | Low–moderate | Smoking, liver disease (obstructive jaundice, hepatitis, alcohol), bowel diseases, peptic ulcer, pancreatitis, renal failure [18] |
| CA 19-9 | 37 U/mL | Pancreatic CA (72–79%), biliary CA (67–73%), gastric CA (42–62%), CRC (19–41%) | Moderate | Benign biliary diseases, benign pancreatic diseases [18] |
| CA 125 | 35 U/mL | Ovarian CA (80%), pancreatic CA (60%), other GI malignancies | Variable | Benign pancreatic and liver disease [18] |
| DUPAN-2 | 150 U/mL | Pancreatic and biliary tract CA (70%) | Moderate | Benign hepatobiliary diseases (hepatitis, cholelithiasis) [18] |
When ARE Tumour Markers Actually Useful?
While tumour markers are poor screening/diagnostic tools, they have specific roles:
- Serial assay after resection — to monitor for disease recurrence (if initially elevated, a rising level post-resection suggests recurrence) [5] [7]
- Prognostic value — high CA 19-9 at diagnosis correlates with worse prognosis in pancreatic CA [7]
- Differentiation — AFP helps distinguish HCC from cholangiocarcinoma. If AFP is very high ( > 400 ng/mL) in a cirrhotic patient, think HCC. [18]
- Note: CA 19-9 requires the Lewis blood group antigen to be expressed — Lewis-negative individuals (5–10% of population) will have falsely normal CA 19-9 even with pancreatic CA [7]
4. Imaging Investigations
This is the heart of the diagnostic workup. The lecture slide states [21]:
Imaging: [21]
- Ultrasound / CT
- Size of bile duct
- Level of obstruction
- Cause of obstruction
- Other associated features
- Malignant disease: staging
- Benign disease: gallstones > complications
Why USG first? It is non-invasive, widely available, cheap, no radiation, and excellent at detecting biliary dilatation and gallstones. It answers the first critical question: Is there biliary obstruction?
| Feature | Details |
|---|---|
| Role | Initial imaging modality for any patient with jaundice [5] [7] [21] |
| What to look for | Size of bile duct for any dilatation ± stones [5] |
| Normal values | Intrahepatic ducts: normally not visible on USG ( < 2–3 mm) [5]; CBD: > 0.8 cm (8 mm) is pathological [5] |
| CBD size rule of thumb | 0.1 cm for every 10 years old (e.g., 6 mm at age 60 is upper normal) [20] — but this applies to post-cholecystectomy or age-related dilatation; in the context of jaundice, any dilatation with symptoms is significant |
| Localising the level | Perihilar lesion = intrahepatic duct dilatation with normal extrahepatic duct; Distal lesion = both intra- and extrahepatic duct dilatation [8] |
| Identifying the cause | Gallstones (echogenic focus with posterior acoustic shadow); mass lesion (hypoechoic pancreatic mass, GB mass, liver mass) |
| Vascular assessment | Duplex USG can evaluate portal vein and hepatic artery involvement — encasement, compression, or thrombosis of portal vein; encasement or occlusion of hepatic artery [8] |
| Limitations | Distal CBD often obscured by bowel gas [20]; operator-dependent; limited in obese patients; cannot stage distant disease well |
Key USG finding: Malignant obstruction is suggested by ductal dilatation ( > 6 mm in adults) in the absence of stones [8]
CT is the definitive cross-sectional imaging for MBO. It simultaneously assesses: the mass, the level of obstruction, vascular involvement, lymph node status, and distant metastases.
For pancreatic cancer specifically, the CT protocol is critical: [14]
CT abdomen with contrast (pancreatic protocol) — thin-sliced triphasic (arterial + pancreatic + portovenous phases) [14]
| Phase | What It Shows | Why |
|---|---|---|
| Arterial phase | Enhancement of celiac axis, SMA, and peripancreatic arteries [7] | Assess for arterial encasement — determines resectability |
| Venous/Pancreatic phase | Attenuation difference between tumour and normal pancreas — increases lesion conspicuity [7] | Pancreatic adenocarcinoma is hypoattenuating (desmoplastic, hypovascular) relative to enhancing normal pancreatic parenchyma |
| Portal venous phase | Enhancement of SMV, splenic vein, and portal vein [7] | Assess for venous encasement/thrombosis — key for resectability |
Key CT findings for different MBO causes:
| Cause | Typical CT Findings |
|---|---|
| CA head of pancreas | Ill-defined hypoattenuating mass within the pancreas [7]; double-duct sign (dilated pancreatic duct + CBD) [14]; pancreatic duct cutoff; parenchymal atrophy; contour abnormalities [7] |
| Cholangiocarcinoma (perihilar) | Hilar mass with upstream intrahepatic duct dilatation; liver atrophy on the affected side; delayed enhancement (desmoplastic tumour) [8] |
| Cholangiocarcinoma (intrahepatic) | Mass lesion in non-cirrhotic liver; peripheral rim enhancement; capsular retraction [8] |
| CA gallbladder | GB wall thickening/mass ± invasion into liver segments IV/V; loss of fat plane with adjacent structures [10] |
| HCC | Arterial-phase hyperenhancement with washout in portal venous phase ("wash-in / wash-out"); cirrhotic liver background [4] |
| Lymphadenopathy | Enlarged porta hepatis / coeliac / para-aortic nodes |
Determine resectability: encasement of SMA, hepatic artery, celiac trunk, SMV, PV [14] [3]
The Double-Duct Sign — Explain It From First Principles
The double-duct sign means simultaneous dilatation of both the CBD and the main pancreatic duct. Why? The CBD and the main pancreatic duct both converge at the ampulla of Vater, running through/adjacent to the head of the pancreas. A mass in the pancreatic head compresses BOTH ducts simultaneously. This sign is highly suggestive of (though not pathognomonic for) CA head of pancreas. Other causes include ampullary carcinoma and chronic pancreatitis.
4.3 Cholangiography — Delineating the Biliary Tree
Once USG/CT has confirmed obstruction and localised the level, you need detailed mapping of the biliary anatomy — this is essential for surgical planning.
- Non-contrast, T2-weighted MRI [20]
- Non-invasive imaging of biliary system and GB [20]
- Superior in delineating the anatomy of biliary tree especially if the system is not completely obstructed [7]
- Largely replaces ERCP as a diagnostic tool [5]
- Avoids complications associated with ERCP, but NOT therapeutic [20]
- When to use: Patients without high suspicion of biliary obstruction (mild bilirubin/ALP elevation, equivocal CT findings) [5]; when anatomy delineation is needed before surgery; when ERCP is not indicated therapeutically
- ERCP is both diagnostic AND therapeutic [5]
- Diagnostic: Direct cholangiogram; brush cytology; forceps biopsy for tissue diagnosis
- Therapeutic: Biliary stent placement; sphincterotomy; stone extraction
- Preferred for distal tumours [3] — the scope goes through the mouth → oesophagus → stomach → D2 → accesses the ampulla → cannulates the CBD from below
- ERCP brush cytology / biopsy: can also relieve jaundice by placing temporary stent [14]
- Complications: Pancreatitis (most common), bleeding, cholangitis, perforation — this is why ERCP has evolved into a mainly therapeutic modality [7]
- Diagnostic: Visualisation of biliary tree by percutaneous needle insertion through the liver into a dilated intrahepatic duct, then injection of contrast
- Therapeutic: External bile drainage by catheter (PTBD) or insertion of indwelling stents
- Preferred to ERCP for stricture/obstruction at or above the level of confluence of hepatic ducts [20] — because ERCP approaches from below and may not be able to pass contrast above a complete hilar obstruction
- Examples: cholangiocarcinoma, PSC, RPC [20]
- Complications: bacteraemia (thus antibiotic prophylaxis required), haemobilia [20]
ERCP vs PTC — When to Use Which?
Think of it anatomically:
- ERCP approaches from below (through the ampulla) → best for distal obstruction (periampullary CA, distal CBD stone/tumour)
- PTC approaches from above (through the liver) → best for proximal/hilar obstruction (Klatskin tumour, PSC, RPC) where the distal CBD may be completely blocked and ERCP cannot get contrast above the stricture [3] [20]
EUS combines endoscopy (placing a probe in the duodenum/stomach) with high-frequency ultrasound — giving you extremely close-up, high-resolution images of the pancreas, bile duct, and surrounding structures.
| Feature | Details |
|---|---|
| Role | Indicated for FNAC or trucut biopsy [5]; staging (local tumour extent, lymph node involvement) |
| CA head of pancreas | CA head of pancreas normally cannot be seen with OGD unless it has invaded through the wall of duodenum; EUS helps to acquire histological diagnosis [5]; detects small pancreatic masses that could be missed by CT [7] |
| CA ampulla / CA duodenum | NO role for EUS — these are visible directly on OGD (they are mucosal lesions at the ampulla/duodenal surface) [5] |
| Cholangiocarcinoma | EUS with brush cytology can be performed but with low sensitivity and specificity [5]; EUS cannot reach the lumen of bile duct in majority of cases → requires mother-baby cholangioscopy [5] |
| Advantage over percutaneous biopsy | EUS-guided FNAC/biopsy preferred over percutaneous USG/CT-guided biopsy — lower risk of tumour seeding [14] |
This is a nuanced and commonly examined point:
Tissue diagnosis is NOT mandatory if potentially resectable [14]
Why not? Because:
- If imaging is classic for pancreatic CA and the tumour is resectable, going to surgery provides both the definitive treatment AND the tissue diagnosis (histology from the resected specimen)
- Delaying surgery for a biopsy can set back treatment
- Percutaneous biopsy carries risk of tumour seeding along the needle tract
When IS tissue diagnosis indicated? [7] [14]:
- CT failed to demonstrate typical features (uncertain diagnosis)
- Before starting neoadjuvant chemotherapy (need confirmed malignancy before giving toxic treatment)
- Suspected secondary metastasis to pancreas (need to identify the primary)
- To exclude mimics like autoimmune pancreatitis or chronic pancreatitis (which respond to steroids/medical treatment, NOT surgery) [7]
- Local evidence of unresectability on staging (patient will receive palliative chemo → need tissue confirmation first)
Methods of tissue diagnosis:
- EUS-guided FNAC/biopsy — preferred (less seeding risk) [14]
- ERCP brush cytology / forceps biopsy — can also relieve jaundice simultaneously [14]
- CT-guided percutaneous biopsy — higher seeding risk; used when EUS not available or not feasible
- Mother-baby cholangioscopy (SpyGlass) — for biliary strictures where EUS cannot reach the duct lumen [5]
Once MBO is confirmed, staging determines resectability — this is the single most important question after diagnosis:
| Modality | What It Assesses |
|---|---|
| CT thorax + abdomen + pelvis (CT TAP) | Distant metastases (lung, liver, peritoneum) [14] |
| PET-CT (FDG) | Evaluate for occult distant metastasis that MRCP and MDCT are unable to detect [8]; particularly useful for cholangiocarcinoma and equivocal CT findings |
| Staging laparoscopy | General exploration of peritoneal surfaces to detect peritoneal/omental/liver surface metastases invisible on CT [7]. Indicated when there is high suspicion of metastatic disease: body/tail tumours, large tumours > 4 cm, high CA 19-9, equivocal ascites/metastasis on CT [7] |
| EUS | Nodal involvement (local/regional LN staging) [3] |
| MRCP | Intrahepatic metastasis (for cholangioCA); biliary tree anatomy [3] |
| Bone scan | If bony metastases suspected (pain, elevated ALP out of proportion) |
| Suspected Cause | Key Investigations | Rationale |
|---|---|---|
| CA head of pancreas | USG → triphasic CT (pancreatic protocol) → EUS-FNAC if tissue needed; ERCP only if stenting needed [14] | CT is both diagnostic and staging; EUS detects small tumours CT misses; tissue Dx NOT mandatory if resectable [14] |
| Perihilar cholangioCA (Klatskin) | USG → CT → MRCP (biliary anatomy) → PTC (preferred over ERCP for proximal obstruction) [3] [20]; PET-CT for occult metastases [8] | PTC approaches from above; MRCP maps extent of biliary involvement for Bismuth-Corlette staging |
| Intrahepatic cholangioCA | USG → CT/MRI (mass in non-cirrhotic liver) → CT-guided biopsy or EUS-FNAC; AFP (to differentiate from HCC) [8] [18] | Presents as a liver mass, not obstructive jaundice; AFP helps distinguish from HCC |
| CA gallbladder | USG → CT → MRI/MRCP → percutaneous biopsy if needed [10]; staging laparoscopy [10] | Often incidental finding on cholecystectomy specimen; if suspected pre-op, stage before surgery |
| HCC | USG → triphasic CT or MRI (arterial enhancement + washout) → AFP [4]; biopsy rarely needed if imaging classic + AFP elevated in cirrhotic patient | Diagnosis can be made on imaging criteria alone in cirrhotic patients (AASLD criteria: arterial hyperenhancement + washout) |
| CA ampulla | OGD with biopsy (directly visible at ampulla!) → CT for staging [5] | EUS has NO role here — the tumour is on the mucosal surface and directly accessible endoscopically |
Why OGD (Not EUS) for CA Ampulla?
The ampulla of Vater opens into the duodenal lumen. An ampullary carcinoma grows INTO the duodenal lumen and is directly visible when the endoscopist passes the scope to D2. You can see it, biopsy it, and make a tissue diagnosis immediately — no need for ultrasound through the wall. This is why the notes specifically state: NO role for EUS in diagnosing CA ampulla of Vater and CA duodenum [5].
7. Specific Imaging Findings — Interpretation Guide
| Finding | Interpretation |
|---|---|
| Dilated intrahepatic ducts + normal CBD | Hilar obstruction (Klatskin, CA GB, HCC) |
| Dilated intrahepatic + extrahepatic ducts + distended GB | Distal CBD obstruction (periampullary CA) |
| Ductal dilatation > 6 mm without stones [8] | Suggests malignant obstruction |
| Hypoechoic pancreatic mass | CA head of pancreas |
| GB wall thickening / polypoid mass | CA gallbladder |
| Focal liver lesion in non-cirrhotic liver | Intrahepatic cholangioCA or metastasis |
| Finding | Interpretation |
|---|---|
| Ill-defined hypoattenuating mass within the pancreas [7] | CA head of pancreas (hypovascular, desmoplastic) |
| Double-duct sign (dilated pancreatic duct + CBD) [7] [14] | CA head of pancreas (compresses both ducts through pancreatic head) |
| Pancreatic duct cutoff + parenchymal atrophy [7] | Upstream pancreatic duct dilatation → distal parenchymal atrophy from disuse |
| Arterial-phase hyperenhancement + portal venous washout | HCC (classic "wash-in / wash-out" pattern) |
| Delayed enhancement at hilum | Perihilar cholangioCA (desmoplastic tumour enhances late) |
| Encasement of SMA, hepatic artery, celiac trunk, SMV, PV [14] | Vascular encasement → unresectable |
| Liver metastases / peritoneal nodules / ascites | Distant metastases → unresectable |
| Finding | Interpretation |
|---|---|
| Abrupt cutoff of CHD at bifurcation | Klatskin tumour |
| "Beaded" appearance of intrahepatic ducts | PSC (alternating strictures and dilatations) |
| Cystic dilatation of extrahepatic duct | Choledochal cyst |
| Smooth tapering of distal CBD | Pancreatic head mass compressing from outside |
| Finding | Interpretation |
|---|---|
| Irregular, asymmetric stricture | Malignant stricture (cholangioCA) |
| Smooth, concentric stricture | Benign stricture (PSC, post-surgical) |
| Rat-tail narrowing of distal CBD | Pancreatic head mass |
| No contrast passing above hilum | Complete hilar obstruction (Klatskin Type IV) |
| "Meniscus" sign at stone | CBD stone (smooth rounded filling defect) |
This is critical because it determines whether the patient gets curative surgery or palliative care:
Unresectable if: [3]
For pancreatic cancer specifically [14]:
- Borderline resectable: Tumour abutting ( ≤ 180° contact) SMA/celiac axis or short-segment encasement of hepatic artery (without extension to celiac); SMV/PV involvement with potential for reconstruction
- Unresectable (locally advanced): Tumour encasing ( > 180°) SMA/celiac axis; unreconstructable SMV/PV occlusion
- Unresectable (metastatic): Any distant metastasis
| Modality | Invasive? | Diagnostic | Therapeutic | Best For | Limitations |
|---|---|---|---|---|---|
| USG abdomen | No | ✅ Duct dilatation, stones, mass | ✗ | First-line for jaundice | Distal CBD obscured by gas; operator-dependent |
| CT triphasic | No* | ✅ Mass, level, staging, vasculature | ✗ | Definitive cross-sectional imaging; resectability | Contrast → nephrotoxicity risk; radiation |
| MRCP | No | ✅ Biliary anatomy | ✗ | Non-invasive cholangiogram; replaces diagnostic ERCP | Not therapeutic; expensive; claustrophobia |
| ERCP | Yes | ✅ Cholangiogram, brush cytology, biopsy | ✅ Stent, sphincterotomy | Distal obstruction; therapeutic drainage | Pancreatitis risk; cannot access above complete hilar obstruction |
| PTC/PTBD | Yes | ✅ Cholangiogram | ✅ External drainage, stent | Proximal/hilar obstruction | Bacteraemia, haemobilia; external drain inconvenience |
| EUS ± FNAC | Yes | ✅ Small masses, LN staging, tissue Dx | ✗ | CA pancreas (tissue Dx with less seeding) | No role for CA ampulla/duodenum; cannot reach bile duct lumen |
| OGD + biopsy | Yes | ✅ Direct visualisation + biopsy | ✗ | CA ampulla, CA duodenum | Limited to mucosal/luminal lesions |
| PET-CT | No* | ✅ Occult distant metastases | ✗ | Cholangiocarcinoma staging; equivocal CT | Expensive; false positives with inflammation |
| Staging laparoscopy | Yes | ✅ Peritoneal disease | ✗ | High-risk patients (body/tail CA, large tumour, high CA 19-9) | Requires GA; decreasing role as CT quality improves |
High Yield Summary
-
MBO management starts with: (1) Establish diagnosis, (2) Delineate level and cause, (3) Treat cholangitis, (4) Definitive treatment [20].
-
Physical exam: Always check for Courvoisier's sign and signs of inoperability (Virchow's node, Blumer's shelf, Sister Mary Joseph nodule, irregular hepatomegaly, ascites) [5].
-
Bloods: Cholestatic LFT pattern (↑ ALP, GGT, conjugated bilirubin); clotting profile (Vitamin K deficiency); tumour markers are NOT diagnostic — neither sensitive nor specific [5] [18].
-
USG is the first-line imaging — establishes duct dilatation, level, stones vs no stones. CBD > 0.8 cm is pathological; intrahepatic ducts normally not visible ( < 2–3 mm) [5].
-
CT triphasic (pancreatic protocol) is the definitive staging investigation — identifies mass, vascular involvement (resectability), LN, metastases [7] [14].
-
Cholangiography: MRCP for non-invasive biliary mapping; ERCP for distal obstruction (diagnostic + therapeutic); PTC for proximal/hilar obstruction [3] [20].
-
Tissue diagnosis is NOT mandatory if tumour is resectable — proceed to surgery. Tissue diagnosis needed for: uncertain diagnosis, neoadjuvant chemo, unresectable disease, suspected mimics (autoimmune pancreatitis, IgG4 cholangitis) [7] [14].
-
EUS-FNAC is preferred over percutaneous biopsy (lower tumour seeding risk) [14]; EUS has NO role for CA ampulla or CA duodenum (use OGD) [5].
-
Staging: CT TAP/PET-CT for distant mets; staging laparoscopy if high suspicion of peritoneal disease [7].
-
Unresectability criteria: Major vessel encasement (SMA, celiac, PV, SMV), bilateral biliary involvement > 2° radicles, distant LN (retropancreatic, paracoeliac, paraaortic), organ metastasis [3] [14].
Active Recall - Diagnosis of MBO
References
[1] Lecture slides: WCS 056 - Painless jaundice and epigastric mass - by Prof R Poon.ppt (1).pdf, p3 [3] Senior notes: maxim.md, Cholangiocarcinoma section (investigations and management) [4] Senior notes: maxim.md, Hepatocellular carcinoma section [5] Senior notes: felixlai.md, Malignant biliary obstruction section (pp. 501–503) [7] Senior notes: felixlai.md, Pancreatic cancer section (pp. 596–598) [8] Senior notes: felixlai.md, Cholangiocarcinoma diagnosis section (pp. 549–551) [10] Senior notes: maxim.md, CA gallbladder section [13] Senior notes: felixlai.md, Acute cholangitis section; maxim.md, Acute cholangitis section [14] Senior notes: maxim.md, Pancreatic carcinoma section (p. 146) [18] Lecture slides: Malignant biliary obstruction.pdf, p8 [20] Senior notes: maxim.md, HBP investigations section; Lecture slides: Malignant biliary obstruction.pdf, p10 and p15 [21] Lecture slides: Malignant biliary obstruction.pdf, p10
Management of Malignant Biliary Obstruction
The management of MBO follows a clear logical sequence. You cannot just "operate" — these patients are among the highest-risk in all of surgery. The lecture provides the overarching framework [20]:
Management: [20]
- Establish diagnosis
- Delineate level and cause of obstruction
- Treat suppurative cholangitis
- Definitive treatment
And a more granular decision-making algorithm from the lecture slides [22]:
MBO → Treat SEPSIS → (1) Assess tumour resectability, (2) Patient general fitness, (3) Liver function reserve → Resectable vs Non-resectable → Palliation [22]
The key decision point is a two-axis assessment [5]:
| Axis | Good | Bad | Outcome |
|---|---|---|---|
| General status | Fit, good nutrition, no major comorbidity | Cachectic, significant comorbidity | Bad → Palliation (PTBD or endoprosthesis) |
| Tumour status | Confined (no metastases, resectable) | Spread (metastases, unresectable) | Spread → Palliation |
| Both good + confined | → | Laparotomy → Radical resection if confirmed confined; Bypass if found to have spread [5] |
Before ANY definitive treatment decision, you must address superimposed biliary sepsis (cholangitis), which is life-threatening:
Palliative care: Treat sepsis, Relieve obstruction (enteric/biliary), Pain control [23]
Antibiotics [5]:
- Augmentin (amoxicillin-clavulanate) OR Cefuroxime (Zinacef) + Metronidazole (Flagyl) [5]
- Why these agents? They cover the typical biliary pathogens: Gram-negative rods (E. coli, Klebsiella) + anaerobes (Bacteroides) + Enterococci [13]
- For severe sepsis/shock: escalate to IV Tazocin (piperacillin-tazobactam) [13]
Emergency biliary drainage [13]:
- Indicated if: Reynold's pentad (fever + jaundice + RUQ pain + shock + altered mental status) or not responding to antibiotics for 24 hours (because antibiotics cannot be adequately secreted into bile when the duct is obstructed) [13]
- QMH practice: ERCP → PTBD → surgical exploration (ECBD with T-tube) [13]
4. Step 2 — Assess the Two Axes
| Parameter | Assessment | Why |
|---|---|---|
| Age / Comorbidity | CXR, ECG, spirometry for hidden medical illness | Major surgery (Whipple, hepatectomy) carries significant morbidity/mortality; must ensure patient can tolerate it |
| Nutrition | LFT (albumin), weight loss history | Cancer cachexia → malnutrition [24] — malnourished patients have poor wound healing, higher infection risk |
| Fluid & Electrolytes | RFT, electrolytes | Dehydration, renal vulnerability from cholemic nephrosis |
| Coagulopathy | CBC, clotting profile (PT/INR) | Liver function impairment → bleeding tendency [24] — must be corrected before any intervention |
Clinical signs of inoperability (found on physical exam) [5]:
- Irregular surface hepatomegaly → liver metastases
- Troisier's sign (Virchow's node) → distant lymphatic spread
- Blumer's shelf → peritoneal metastases
- Sister Mary Joseph nodules → peritoneal metastases
- Ascites → peritoneal carcinomatosis
Radiological signs of inoperability [5] [3]:
- LN metastasis (retropancreatic, paracoeliac, paraaortic)
- Distant metastasis (liver, lung, peritoneum)
- Arterial involvement (SMA / Celiac axis) — encasement > 180°
- Venous involvement (SMV / PV) — NOTE: Portal vein involvement is NOT an absolute contraindication [5]
- Extensive involvement of biliary tree (bilaterally > 2° radicles) [3]
Portal Vein Involvement — NOT an Absolute Contraindication!
This is a commonly examined point. Unlike arterial encasement (SMA, celiac axis), portal vein involvement can sometimes be managed with en-bloc venous resection and reconstruction. The goal is R0 resection — microscopically clear margins. QMH will consider PV resection on a case-by-case basis depending on the extent of involvement. [5]
Why is malignant biliary obstruction so risky for operation? [24]
- Cancer cachexia → malnutrition
- Liver function impairment
- Superimposed biliary infection
These three problems must be addressed before taking a patient to theatre:
| Problem | Pre-op Measure |
|---|---|
| Cancer cachexia → malnutrition | Nutritional support — enteral feeding (NG/NJ tube or oral supplements) preferred over TPN; correct hypoalbuminaemia [5] |
| Liver derangement → bleeding tendency | IV Vitamin K and FFP during surgery [5] — Vitamin K corrects the synthetic deficit (factors II, VII, IX, X); FFP provides immediate clotting factor replacement for surgery |
| Superimposed biliary infection | Antibiotic cover [5] — broad-spectrum as above; ensure sepsis is controlled before elective surgery |
5.1 Pre-operative Biliary Drainage
This is a nuanced and commonly examined topic:
Relief of biliary obstruction before surgery [25]:
- ERCP and endoprosthesis
- Percutaneous transhepatic biliary drainage
- Target level: Serum bilirubin < 50 µmol/L or < 20 µmol/L for concomitant partial hepatectomy [25]
Why drain pre-operatively? [5]
- Minimise risk of developing cholangitis while awaiting surgery
- Relieve jaundice and pruritus
- Prevent complications of prolonged cholestasis (renal impairment, coagulopathy, immune dysfunction)
- Allow time for neoadjuvant therapy in locally advanced disease
The debate — to drain or not to drain? [5]
Theoretically: Do NOT need to drain if no sepsis + early surgery can be offered within 1–2 weeks [5]
- Pre-operative biliary drainage increases risk of serious complications (pancreatitis, cholangitis, stent occlusion) even in expert hands
- Surgical-related complications are comparable even without drainage
Practically (QMH): Drain ALL patients since QMH cannot offer early surgery [5]
- Whipple operation has to wait for 6–8 weeks and the chance of biliary sepsis will be very high without drainage while waiting [5]
Advantages of pre-op drainage [5]:
- Minimise cholangitis risk during the wait
- Relieve symptoms (jaundice, pruritus)
- Allow neoadjuvant therapy
Disadvantages of pre-op drainage [5]:
- Increase the number of interventions and associated costs
- Increase risk of procedure-related complications: cholangitis, pancreatitis, bleeding, perforation, stent blockage
Target Bilirubin Levels
Bilirubin < 50 µmol/L for standard surgery (e.g., Whipple) Bilirubin < 20 µmol/L for surgery involving concomitant partial hepatectomy (e.g., Klatskin tumour resection) [25]
Why the stricter target for hepatectomy? Because you are removing liver parenchyma — the remaining liver (future liver remnant, FLR) must be functional enough to sustain the patient. A cholestatic liver has impaired regenerative capacity, and operating on it with high bilirubin dramatically increases the risk of post-hepatectomy liver failure.
6. Curative Treatment — Surgical Resection
Role of surgery: [26]
- Oncological clearance — R0 resection
- Relieve obstruction
- Pain control
Laparotomy is indicated if patient's general status is good and tumour is confined [5]:
| Pathology | Curative Operation | Key Details |
|---|---|---|
| Periampullary carcinoma (CA head of pancreas, CA ampulla, CA duodenum, CA distal CBD) | Whipple operation (Pancreaticoduodenectomy) [5] | Removes: head of pancreas, duodenum, distal CBD, gallbladder, distal stomach (or pylorus-preserving variant). Reconstruction: pancreaticojejunostomy + hepaticojejunostomy + gastrojejunostomy (3 anastomoses) |
| PPPD (Pylorus-preserving pancreaticoduodenectomy) — can be considered if R0 achievable [5] | Shorter operative time, less blood loss, improved post-op nutrition, lower risk of dumping, marginal ulceration, and bile reflux gastritis [5] | |
| CA gallbladder | Radical cholecystectomy [5] | Removal of tumour, part of liver (segment 4b and 5), and draining LNs [5]; intra-op frozen section of cystic duct margin [10] |
| Klatskin tumour (perihilar CC) | Major hepatectomy + Caudate lobectomy + extrahepatic bile duct resection + portal LN dissection + Roux-en-Y hepaticojejunostomy [5] [3] | Caudate lobe resected because its bile ducts drain directly into the hepatic duct bifurcation and are almost always involved by Klatskin tumours |
| Intrahepatic cholangioCA | Partial hepatectomy + portal LN dissection [3] | Treated like a liver tumour rather than a bile duct tumour |
| Distal CBD cholangioCA | Whipple's procedure [3] | Same as for periampullary CA — the distal CBD is resected en bloc with pancreatic head and duodenum |
Let's explain from first principles why the Whipple operation (pancreaticoduodenectomy) requires resection of so many structures:
The head of the pancreas, the duodenum (D1–D3), the distal CBD, and the gallbladder share an intimate blood supply (gastroduodenal artery, inferior pancreaticoduodenal artery) and anatomical connections (the CBD runs through the pancreatic head; the pancreatic duct and CBD converge at the ampulla in D2). You cannot remove the pancreatic head without devascularising the duodenum, and you cannot leave the distal CBD behind without leaving residual tumour. Therefore, all these structures must come out as a single specimen.
Three reconstruction anastomoses after Whipple:
- Pancreaticojejunostomy — reconnects remaining pancreatic body/tail to jejunum (so pancreatic juice drains into bowel)
- Hepaticojejunostomy — reconnects remaining hepatic duct to jejunum (so bile drains into bowel)
- Gastrojejunostomy (or duodenojejunostomy if PPPD) — reconnects stomach to jejunum (so food can pass into bowel)
- If FLR (future liver remnant) inadequate: portal vein embolisation (PVE) to induce atrophy of affected segment + hypertrophy of unaffected segments [3]
- Why? Blocking the portal vein branch to the side with the tumour causes that side to atrophy while the healthy side hypertrophies over 4–6 weeks — increasing the volume of functional liver that will remain after resection. Without this, post-hepatectomy liver failure is a major risk.
- Pre-operative drainage (ERCP / PTBD) considered if biliary sepsis / poor LFT [3]
- Open approach for cholecystectomy is generally recommended since port site recurrences and late peritoneal metastasis associated with bile spillage are reported with laparoscopic approach [10]
- Open cholecystectomy with intra-op frozen section [10]:
- Stage I disease (T1N0, confined to mucosa): no further treatment required
- Higher stage disease (extending to serosa/transmural): extended cholecystectomy [10]
- En-bloc resection of gallbladder with rim of liver ≥ 2 cm adjacent to gallbladder bed
- Segmental hepatectomy (segments IVb, V)
- Extrahepatic bile duct resection (if cystic duct involved)
- Regional lymphadenectomy (porta hepatis LN) [10]
Intra-op frozen section of cystic duct [10]:
- Positive → regional LN dissection + extrahepatic bile duct resection with Roux-en-Y hepaticojejunostomy [10]
- Negative → regional LN dissection only
Absolute contraindications for radical resection of CA gallbladder [10]:
- Liver metastasis
- Peritoneal metastasis
- Malignant ascites
- Encasement or occlusion of major vessels (hepatic artery / portal vein)
- Involvement of paraaortic, pericaval, SMA, or celiac artery lymph nodes (considered distant metastatic disease)
- Extensive involvement of the hepatoduodenal ligament
| Cancer | Adjuvant Chemotherapy |
|---|---|
| CA pancreas | Indicated for ALL resected CA pancreas; start within 12 weeks post-op [14]: FOLFIRINOX (folinic acid, 5-FU, irinotecan, oxaliplatin) or Gemcitabine + capecitabine × 6 months [14] |
| Cholangiocarcinoma | Adjuvant chemotherapy has survival advantage for resected cholangioCA: Gemcitabine, Capecitabine, or Leucovorin-modulated 5-FU [8] |
| CA pancreas — Neoadjuvant | Neoadjuvant chemoradiotherapy to downstage patients with borderline resectable disease [7] |
7. Palliative Treatment — For Unresectable Disease
Only 15–20% of patients with pancreatic cancer are surgical candidates due to late presentation [7]. For the majority, palliation focuses on three pillars [23] [7]:
Palliative care: Treat sepsis, Relieve obstruction (enteric/biliary), Pain control [23]
7.1 Relieving Biliary Obstruction — Stenting vs PTBD vs Surgical Bypass
ERCP with endoprosthesis is ALWAYS 1st line regardless of the level of obstruction especially for periampullary carcinoma [5]
Exceptions (when ERCP is NOT feasible) [5]:
- Contraindications for ERCP (e.g., structural upper GI abnormalities, partial gastrectomy with Billroth II or Roux-en-Y anastomosis — altered anatomy prevents scope from reaching the ampulla)
- Multiple stenting required or difficulty in reaching intrahepatic bile ducts (proximal/hilar obstruction)
| Plastic Stent | Metallic Stent (SEMS) | |
|---|---|---|
| Durability | Shorter patency (weeks-months) | Longer patency (months) |
| Removability | Can be removed and exchanged easily | Cannot be removed (especially uncovered) |
| Cost | Cheaper | More expensive |
| When to use | Temporary drainage (pre-op bridge to surgery); uncertain diagnosis | Confirmed inoperable malignancy [5] — when you know the patient will not go to surgery |
| Covered vs Uncovered | N/A | Uncovered stents preferred: lower risk of occluding branches of biliary system [3]; but uncovered stents can have tumour ingrowth through the mesh |
- Indicated when ERCP is unsuccessful, unavailable, or contraindicated [5]
- ERCP with endoprosthesis is preferred over PTBD because [5]:
- PTBD is technically more difficult
- Bleeding is common due to puncture of hepatic artery or portal vein before reaching the bile duct (Portal triad) [5]
Types of PTBD [5]:
- Simple external PTBD: Short-term drainage to bridge to surgery; prone to electrolyte and fluid loss due to bile output
- External-internal type PTBD: Long-term palliation; catheter passes through the obstruction into the duodenum; side-holes above AND below the obstruction allow internal drainage; can be capped to internalise flow [5] [27]
PTBD complication management [5]:
- If bleeding after PTBD insertion:
- Stabilise and resuscitate
- Clamp the PTBD catheter
- Perform cholangiogram by injecting contrast into PTBD to determine if catheter is in hepatic artery or portal vein
- Remove catheter slowly to control bleeding — do NOT remove immediately as this converts the situation into free haemoperitoneum [5]
Complications of PTBD [5]:
- Cholangitis / Biliary sepsis
- Haemobilia (communication of the tract with a major vascular structure)
Palliative bypass is used when endoscopic/percutaneous approaches fail or when unresectability is discovered at laparotomy [14]:
| Bypass Type | Components | Indication |
|---|---|---|
| Single bypass | Hepaticojejunostomy (anastomosis between common hepatic duct and jejunum) [5] | Biliary obstruction alone. Choledochojejunostomy not performed at QMH [5]. Choledochoduodenostomy NOT advised because of proximity of duodenum to tumour [7] |
| Double bypass | Single bypass + Gastrojejunostomy [5] | Biliary + enteric obstruction — especially CA head of pancreas which compresses both bile duct AND duodenum → GOO [5] |
| Triple bypass | Double bypass + Pancreaticojejunostomy [5] | Biliary + enteric + pancreatic duct obstruction. Pancreatic duct is small and anastomosis is difficult → high risk of anastomotic leakage [5] |
When tumour found unresectable during laparotomy [14]:
- Double bypass surgery (gastric bypass + biliary bypass)
- Obtain transduodenal trucut biopsy ± celiac plexus block [14]
Prospective randomised trials comparing percutaneous or endoscopic drainage with surgical biliary bypass: [28]
| Stent / PTBD | Surgical Bypass | |
|---|---|---|
| Initial morbidity & mortality | Lower | Higher |
| Hospital stay | Shorter | Longer |
| Late biliary complications | More (stent occlusion, cholangitis) | Fewer |
| Re-interventions | More (OR 7.23) [28] | Fewer |
| Long-term results | Worse | Better |
Clinical decision: If the patient has a short life expectancy ( < 3–6 months), stenting is preferred (lower initial morbidity, avoids major surgery). If the patient has longer expected survival or unresectability is found at laparotomy, surgical bypass gives better long-term palliation.
CA head of pancreas can compress the duodenum → GOO:
- Endoscopic duodenal wall stenting [7] — self-expanding metallic stent placed endoscopically across the duodenal stricture
- Gastrojejunostomy (GJ) — surgical bypass of the duodenal obstruction [5]
- Percutaneous endoscopic gastrostomy (PEG) placement for decompression [7] — in patients unfit for any other intervention
Pain in MBO is primarily from retroperitoneal tumour infiltration of the celiac plexus (especially in CA body/tail of pancreas):
- Step 1: Analgesic ladder — paracetamol → NSAIDs → opioids (morphine) [7]
- Step 2: Endoscopic USG / CT-guided celiac plexus neurolysis (celiac plexus block) [5] [7]
- How it works: Injection of alcohol (ethanol) or phenol into/around the celiac plexus (located anterior to the aorta at T12–L1) → chemical destruction of the sympathetic nerve fibres that transmit visceral pain from the upper abdomen
- Adequate pain control is explicitly listed as a component of palliative care [5]
- Step 3: Short-course radiotherapy for local pain relief [14]
| Cancer | Regimen | Notes |
|---|---|---|
| CA pancreas | Gemcitabine — symptomatic improvement, improved pain control, performance status, and weight gain [7]; FOLFIRINOX for fitter patients [14] | Erlotinib (EGFR inhibitor), Capecitabine, 5-FU also used [7] |
| Cholangiocarcinoma | Gemcitabine + Cisplatin (ABC-02 trial); Capecitabine; 5-FU [8] | |
| Photodynamic therapy — injection of IV porphyrin photosensitiser followed by endoscopic application of light of specific wavelength to the tumour bed [8] | Novel palliative approach for hilar cholangioCA |
If the pancreatic duct is also obstructed or pancreatic parenchyma is destroyed:
- Exocrine insufficiency → Pancreatic enzyme replacement (Creon)
- Endocrine insufficiency → OHA / insulin for diabetes management [14]
When both ERCP and PTBD fail (or are contraindicated), EUS-guided transmural drainage offers alternatives:
| Procedure | Description |
|---|---|
| EUS-guided choledochoduodenostomy (CDS) | Create a fistula between CBD and D1 under EUS guidance, then place a lumen-apposing metal stent (LAMS) |
| EUS-guided hepaticogastrostomy (HGS) | Create a fistula between a left intrahepatic bile duct and the stomach |
| EUS-guided gallbladder drainage (EGBD) | Create a cholecystoduodenal fistula — used when biliary tree cannot be accessed |
These are increasingly available at specialised centres (including QMH) as rescue techniques.
9. Special Considerations — Pre-operative Drainage in Detail
| Method | Preferred When | Advantages | Disadvantages |
|---|---|---|---|
| ERCP + stent | Distal obstruction; periampullary CA; always first line [5] | Less invasive than PTBD; internal drainage (no external bag); can obtain brush cytology simultaneously | Cannot always cross hilar obstruction; complications (pancreatitis, cholangitis) |
| PTBD | Proximal/hilar obstruction; ERCP failed or contraindicated [5] | Higher success rate for hilar lesions; easy output monitoring | External drainage (fluid/electrolyte loss); bleeding risk; bacteraemia; patient discomfort |
- Use of unilateral or bilateral stents is controversial for hilar obstruction [8]
- Unilateral: Drains only one side; simpler; lower complication rate; but may not adequately relieve jaundice if both lobes are obstructed (Bismuth Type IV)
- Bilateral: Drains both lobes; better jaundice relief; but technically more difficult; higher complication rate
- Endoscopic method is preferred due to less inconvenience without external drainage, lower risk of bile leaks and bleeding [8]
- Percutaneous method has a higher success rate of palliation of jaundice and lower risk of early cholangitis but external drainage is inconvenient [8]
| Clinical Scenario | Management |
|---|---|
| MBO + cholangitis (sepsis) | IV antibiotics → emergency biliary drainage (ERCP first line) → once sepsis controlled → assess resectability |
| MBO, resectable, fit patient | Pre-op optimisation (Vitamin K, drainage to bilirubin < 50, nutrition, antibiotics) → laparotomy → radical resection |
| MBO, resectable, fit, but Klatskin with planned hepatectomy | Pre-op drainage to bilirubin < 20 µmol/L [25]; consider PVE if FLR inadequate → major hepatectomy + caudate lobectomy |
| MBO, unresectable on imaging | Tissue diagnosis (EUS-FNAC) → palliative stenting (SEMS) + palliative chemotherapy ± celiac plexus block |
| MBO, unresectable found at laparotomy | Palliative bypass (double bypass for CA head of pancreas) + transduodenal biopsy ± celiac plexus block [14] |
| MBO + GOO | Double bypass (hepaticojejunostomy + gastrojejunostomy) or duodenal stent [5] |
| MBO, unfit patient | PTBD or endoscopic stenting only; best supportive care |
High Yield Summary
-
Management framework: Treat sepsis → Assess (general status + tumour status) → Resectable + Fit → Laparotomy; Unresectable or Unfit → Palliation [20] [22].
-
MBO is high-risk for surgery because of: cancer cachexia → malnutrition, liver function impairment, superimposed biliary infection [24].
-
Pre-op measures: IV Vitamin K + FFP (coagulopathy), nutritional support (cachexia), antibiotics (infection), pre-op biliary drainage (target bilirubin < 50 µmol/L; < 20 µmol/L if hepatectomy planned) [25].
-
QMH practice: Drain ALL patients pre-op because Whipple wait time is 6–8 weeks [5].
-
ERCP with endoprosthesis is ALWAYS 1st line for biliary drainage; PTBD if ERCP fails/contraindicated [5].
-
Metallic stents for confirmed inoperable disease (durable, longer patency, cannot be removed); plastic stents for temporary pre-op drainage (removable) [3] [5].
-
Curative surgery by pathology: Periampullary → Whipple; CA GB → Radical cholecystectomy; Klatskin → Major hepatectomy + caudate; Intrahepatic CC → Partial hepatectomy; Distal CC → Whipple [5] [3].
-
Palliative bypass: Single (hepaticojejunostomy), Double (+ gastrojejunostomy for GOO), Triple (+ pancreaticojejunostomy — high leak risk) [5].
-
Stent/PTBD vs Surgical bypass: Stent = lower initial morbidity, more re-interventions; Surgery = higher initial morbidity, better long-term results [28].
-
Role of surgery: Oncological clearance (R0 resection), relieve obstruction, pain control [26]. Portal vein involvement is NOT an absolute contraindication [5].
Active Recall - Management of MBO
References
[3] Senior notes: maxim.md, Cholangiocarcinoma management section [5] Senior notes: felixlai.md, Malignant biliary obstruction section (pp. 503–506) [7] Senior notes: felixlai.md, Pancreatic cancer treatment section (pp. 598–600) [8] Senior notes: felixlai.md, Cholangiocarcinoma treatment section (pp. 550–551) [10] Senior notes: maxim.md, CA gallbladder section; felixlai.md, CA gallbladder treatment section (pp. 568–570) [13] Senior notes: felixlai.md, Acute cholangitis treatment section (pp. 522–525); maxim.md, Acute cholangitis section [14] Senior notes: maxim.md, Pancreatic carcinoma section (pp. 146–148) [20] Lecture slides: Malignant biliary obstruction.pdf, p15 [22] Lecture slides: Malignant biliary obstruction.pdf, p18–19 [23] Lecture slides: Malignant biliary obstruction.pdf, p30 [24] Lecture slides: WCS 056 - Painless jaundice and epigastric mass - by Prof R Poon.ppt (1).pdf, p63 [25] Lecture slides: WCS 056 - Painless jaundice and epigastric mass - by Prof R Poon.ppt (1).pdf, p67 [26] Lecture slides: Malignant biliary obstruction.pdf, p19 [27] Senior notes: maxim.md, Methods of biliary drainage section (p. 7) [28] Lecture slides: Malignant biliary obstruction.pdf, p35
Complications of Malignant Biliary Obstruction
Complications of MBO can be organised into three categories: (A) complications of the disease itself (i.e., what the biliary obstruction and cancer do to the patient), (B) complications of diagnostic/palliative interventions (stenting, PTBD, ERCP), and (C) complications of curative surgery. Each has a clear pathophysiological basis. Let's go through every one from first principles.
1. Complications of the Disease Itself
Why does it happen?
Bile stasis from obstruction removes the normal protective mechanisms of the biliary tree — continuous flushing action, bacteriostatic bile salts, mucosal IgA, and the sphincter of Oddi barrier [13]. Bacteria ascend from the duodenum into the stagnant, obstructed bile. Once biliary pressure exceeds the secretory pressure of the hepatocytes (normal ductal pressure: 7–14 cm H₂O; increased biliary pressure > 25 cm H₂O), bacteria are forced into the hepatic venous and lymphatic system (cholangiovenous and cholangiolymphatic reflux), leading to bacteraemia and septic shock [29].
A critical additional point from the lecture: Excretion of antibiotics is impaired in biliary obstruction [29] — meaning even if you give IV antibiotics, they cannot concentrate in the obstructed bile where the infection is. This is why biliary drainage is mandatory [29] in cholangitis complicating MBO.
Clinical features [13]:
- Charcot's triad (50–70%): Fever, RUQ pain, jaundice
- Reynold's pentad ( < 10%): Charcot's triad + shock + altered mental status → indicates suppurative cholangitis (pus under pressure in bile duct) with multi-organ failure
Common organisms [13]:
- Gram-negative: E. coli, Klebsiella pneumoniae, Enterobacter spp., Bacteroides fragilis
- Gram-positive: Enterococcus spp.
- If stent present: Pseudomonas (biofilm on foreign body)
Why is Cholangitis in MBO Especially Dangerous?
Three synergistic factors:
- Impaired immune system — biliary obstruction suppresses reticuloendothelial (Kupffer cell) function and cell-mediated immunity [24] [30]
- Impaired antibiotic delivery — antibiotics are secreted into bile; obstructed bile ducts cannot concentrate antibiotics at the site of infection [29]
- Continuous bacterial source — the stagnant bile above the obstruction serves as a perpetual culture medium; until the obstruction is drained, infection cannot be eradicated
Why does it happen?
Cancer cachexia is a multifactorial syndrome driven by:
- Tumour-derived cytokines (TNF-α, IL-6, IL-1) → systemic inflammation → skeletal muscle proteolysis → wasting
- Anorexia — central appetite suppression from cytokines
- Fat malabsorption — bile salts cannot reach the gut → impaired emulsification of dietary fat → steatorrhoea → caloric loss
- Impaired protein synthesis — cholestatic liver has reduced synthetic capacity → hypoalbuminaemia, muscle wasting
Cancer cachexia → malnutrition is explicitly listed as a reason MBO is high-risk for surgery [24].
Why does it happen?
Prolonged obstruction of bile flow has progressive hepatotoxic effects:
- Bile acid cytotoxicity — retained bile acids (hydrophobic bile acids like lithocholic acid) are directly toxic to hepatocyte membranes, causing apoptosis and necrosis
- Secondary biliary cirrhosis — chronic obstruction → periportal fibrosis → eventually cirrhosis
- Endotoxaemia — Kupffer cells are dysfunctional → gut-derived endotoxins enter systemic circulation → further hepatocyte injury
- Impaired gluconeogenesis and impaired ketogenesis [30] — the cholestatic liver cannot adequately perform its metabolic functions, leading to metabolic decompensation
Why does it happen?
- Conjugated bilirubin and bile salts are directly nephrotoxic — they cause tubular necrosis
- Endotoxaemia causes renal vasoconstriction → reduced renal perfusion
- Dehydration (poor oral intake, vomiting from GOO)
- Historical studies showed: higher anastomotic leak, haemorrhage, and renal failure in jaundiced patients undergoing surgery [31]
This is why the lecture specifically lists mannitol, dopamine to prevent renal failure as one of the measures to reduce surgical complications [32].
Why does it happen? Impaired clotting factor synthesis [30]:
- Vitamin K (fat-soluble) cannot be absorbed without bile salts in the gut
- Vitamin K is a cofactor for hepatic synthesis of clotting factors II, VII, IX, X (and protein C, S)
- → Prolonged PT/INR → increased bleeding risk
Pathophysiological effects of malignant biliary obstruction: [30]
- Endotoxaemia
- ↓ Reticuloendothelial function
- ↓ Cell-mediated immunity
This creates a state of functional immunosuppression — the patient is vulnerable to infection (not just biliary, but also wound infections, pneumonia, urinary infections post-operatively).
| Deranged Function | Mechanism | Clinical Consequence |
|---|---|---|
| Impaired protein synthesis | Cholestatic liver → reduced hepatocyte function | Hypoalbuminaemia, oedema, poor wound healing |
| Impaired clotting factor synthesis | Vitamin K malabsorption + reduced hepatic synthesis | Coagulopathy, bleeding tendency |
| Impaired gluconeogenesis | Liver unable to generate glucose from non-carbohydrate sources | Hypoglycaemia (especially during perioperative fasting) |
| Impaired ketogenesis | Liver unable to produce ketone bodies from fatty acids | Cannot provide alternative fuel substrate during starvation → metabolic decompensation |
Occurs specifically with CA head of pancreas — the tumour compresses both the CBD (causing jaundice) AND the duodenum (causing GOO) [5]. Presents with non-bilious projectile vomiting of undigested food, early satiety, weight loss, and succussion splash on examination.
Can occur when tumour obstructs the main pancreatic duct (especially in periampullary or pancreatic head cancers) → back-pressure → premature activation of pancreatic enzymes → autodigestion [7].
2. Complications of Diagnostic and Palliative Interventions
ERCP is the workhorse intervention for MBO, but it carries significant procedural risks:
| Complication | Incidence | Mechanism | Management |
|---|---|---|---|
| Post-ERCP pancreatitis | ~5–7% | Trauma to papilla / pancreatic duct orifice during cannulation → pancreatic duct oedema → impaired outflow → autodigestion | Conservative (NPO, IV fluids, analgesia); prophylactic rectal indomethacin reduces risk |
| Ascending cholangitis / sepsis | ~1% | Injection of contrast into obstructed system → bacteria forced into bloodstream; stent blockage → stasis → infection | IV antibiotics; re-drainage (stent exchange or PTBD) |
| Post-sphincterotomy bleeding | ~2% [27] | Cutting of sphincter of Oddi involves cutting across the biliopancreatic septum which contains branches of the retroduodenal artery | Endoscopic haemostasis (adrenaline injection, clip); correct coagulopathy |
| Perforation | ~1% [27] | Sphincterotomy extends beyond the intramural CBD into the retroperitoneal space; or scope-related duodenal perforation | Conservative management if contained; surgical repair if free perforation |
| Cholecystitis | Uncommon | Stent occluding cystic duct orifice → bile stasis in GB → infection | Antibiotics ± percutaneous cholecystostomy |
| Complication | Mechanism | Management |
|---|---|---|
| Stent occlusion | Sludge / tumour ingrowth / tumour overgrowth [5] — bile sludge forms biofilm on stent; uncovered metal stents allow tumour to grow through the mesh interstices; tumour overgrowth at stent ends | Managed by sweeping or placing a new stent [3]; if recurrent, consider surgical bypass |
| Stent migration [3] | Peristalsis or inadequate anchoring can displace the stent proximally or distally | Endoscopic retrieval and replacement |
| Cholangitis | Occluded stent → bile stasis → bacterial overgrowth | Stent exchange; IV antibiotics |
| Cholecystitis | Stent covering the cystic duct orifice (especially with covered SEMS) | Uncovered stents preferred: lower risk of occluding branches of biliary system [3] |
Plastic vs Metallic stent patency [33]:
- Metal stents: 15–39 weeks patency
- Plastic stents: 7–20 weeks patency
- Metallic stents have significantly less recurrent biliary obstruction prior to death [33]
| Complication | Mechanism | Management |
|---|---|---|
| Cholangitis / biliary sepsis | Introducing bacteria during percutaneous puncture; ascending infection through the catheter tract; antibiotic prophylaxis required [5] | IV antibiotics; catheter exchange |
| Haemobilia | Communication of the percutaneous tract with a major vascular structure [5] — hepatic artery or portal vein punctured during the percutaneous approach through the liver (the portal triad lies at the hilum) | Stabilise and resuscitate → clamp PTBD catheter → perform cholangiogram via PTBD to identify whether catheter is in hepatic artery or portal vein → remove catheter slowly; do NOT remove immediately (converts to free haemoperitoneum) [5] |
| Fluid and electrolyte loss | External drainage diverts bile (containing sodium, chloride, bicarbonate) outside the body → dehydration, hyponatraemia, metabolic acidosis | Monitor daily output and replace losses IV; consider conversion to internal-external drainage |
| Catheter dislodgement | Movement or inadequate fixation | Re-insertion under fluoroscopic guidance |
| Bile leak / biliary peritonitis | Bile leaks around the catheter site into the peritoneal cavity | Catheter adjustment; drainage of peritoneal collection |
| Pleural transgression | Right-sided PTBD → intercostal approach may cross the pleural space → pneumothorax or pleural effusion | Left hepatic duct preferred because the subcostal route is less painful and less likely to transgress the pleural space [5] |
The lecture specifically highlights this debate:
Pre-op biliary drainage has increased risk of serious complications: [34]
- Pancreatitis (7%), cholangitis (26%), blocked stent (15%), bleeding (2%), perforation (2%)
- Surgery-related complications were comparable (with or without pre-op drainage)
- Routine pre-op biliary drainage in patients undergoing surgery for CA pancreas increases rate of complications [34]
The jaundice itself also causes problems if left undrained [31]:
Jaundice → coagulopathy, malabsorption, malnutrition, and immune dysfunction → higher anastomotic leak, haemorrhage, and renal failure [31]
This creates a therapeutic dilemma — drain (and risk procedure-related complications) vs. don't drain (and risk cholestasis-related complications). As discussed in the management section, the practical QMH approach is to drain all patients because surgery cannot be performed early [5].
3. Complications of Curative Surgery
3.1 Post-Whipple (Pancreaticoduodenectomy) Complications
Historical data shows MBO carries a very high operative mortality [35]:
Malignant biliary obstruction postoperative mortality: [35]
- Nakayama 1978: 28%
- Dixon 1983: 26%
- Lai 1992: 27%
Modern mortality at high-volume centres is now 2–5%, but morbidity remains substantial (30–50%).
| Complication | Mechanism | Notes |
|---|---|---|
| Anastomotic leak | Three anastomoses are at risk; Risk: PJ (30%) > CJ > GJ [14] — because pancreatic juice contains digestive enzymes (trypsin, lipase, amylase) that erode the anastomosis, and the pancreatic duct is often small and soft | Severe PJ leak may require distal pancreatectomy [14]; Somatostatin analogue (e.g., octreotide) does NOT reduce risk [14] |
| Pancreatic fistula (most common major complication) | Abnormal connection between the pancreas and adjacent structures [14]; Post-op definition: drain output of any volume after post-op Day 3 with drain amylase > 3× ULN [14] | Risk factors: high BMI, soft pancreas, narrow duct [14] |
| Delayed gastric emptying (DGE) | Common after PPPD; mechanisms: injury to nerve of Latarjet (vagal branch supplying antrum/pylorus), disrupted pacemaker cells (interstitial cells of Cajal in duodenum removed), reduced CCK (high concentration found in duodenum — duodenum resected) [14] | Treated with prokinetics (metoclopramide, erythromycin); NG drainage if severe |
| Intra-abdominal haemorrhage | Erosion of GDA stump pseudoaneurysm by pancreatic juice from a fistula; or surgical bleeding | GDA pseudoaneurysm → intraabdominal haemorrhage / UGIB [14]; requires angiographic embolisation or surgical haemostasis |
| Intra-abdominal abscess / wound infection | Anastomotic leak → contamination → abscess; immunosuppression from MBO (impaired cell-mediated immunity) | CT-guided percutaneous drainage; IV antibiotics |
| Post-operative renal failure | Cholemic nephrosis + hypovolaemia + sepsis | Mannitol, dopamine to prevent renal failure [32] |
| Multi-organ failure | Cascade from sepsis (leak → abscess → bacteraemia → SIRS → MOF) | ICU support; may be fatal |
Measures to reduce complications related to surgery for MBO: [32]
- Nutritional support
- Vitamin K
- FFP during surgery
- Antibiotic cover
- Mannitol, dopamine to prevent renal failure
- H₂ antagonist
Why H₂ antagonist? [32] Patients undergoing major HPB surgery are at high risk of stress ulceration — the combination of physiological stress, fasting, and potential ICU admission creates a perfect storm for gastric acid hypersecretion and mucosal ischaemia. H₂ blockers (ranitidine) or PPIs reduce this risk.
| Complication | Mechanism |
|---|---|
| Exocrine insufficiency → malabsorption and steatorrhoea | Removal of pancreatic head → reduced pancreatic enzyme output → fat maldigestion. Managed with pancreatic enzyme replacement (Creon) [14] |
| Endocrine insufficiency → diabetes mellitus | Removal of pancreatic head → loss of islet cells. New-onset DM in 16% post-Whipple [14]. Managed with OHA / insulin [14] |
| Gastric stasis | Especially post-PPPD (pylorus preserved but denervated) |
| Dumping syndrome | After standard Whipple (partial gastrectomy) — rapid gastric emptying of hyperosmolar chyme into jejunum → fluid shifts → vasomotor symptoms |
| Marginal ulceration | Anastomotic ulcer at gastrojejunostomy site — from loss of duodenal buffering + acid exposure |
| Bile reflux gastritis | If gastrojejunostomy allows reflux of bile into the gastric remnant |
This deserves special attention because it is the most feared complication after pancreatic surgery:
Classification (International Study Group of Pancreatic Fistula — ISGPF) [14]:
| Grade | Definition | Management |
|---|---|---|
| Biochemical leak | Drain amylase > 3× ULN but asymptomatic | Observation; drain when output diminishes |
| Grade B | Persistent drainage > 3 weeks, requiring change in management, signs of infection but no organ failure | Antibiotics; CT-guided drainage; TPN |
| Grade C | Unstable, requires re-operation, risk of organ failure | Surgical re-exploration; may need completion pancreatectomy |
Downstream consequences of pancreatic fistula [14]:
- Pseudocyst — walled-off collection of pancreatic juice
- High-output fistula → dehydration, malnutrition, metabolic acidosis (loss of HCO₃⁻ in pancreatic juice)
- GDA pseudoaneurysm → intraabdominal haemorrhage / UGIB (pancreatic enzymes erode the GDA stump)
- Portal vein thrombosis / Splenic vein thrombosis (peripancreatic inflammation)
- Pancreatic ascites (leak into peritoneal cavity)
| Complication | Mechanism |
|---|---|
| Post-hepatectomy liver failure (PHLF) | Inadequate future liver remnant (FLR) → insufficient hepatocyte mass to maintain synthetic, metabolic, and excretory functions. This is why bilirubin must be < 20 µmol/L before hepatectomy [25] and PVE is performed if FLR is inadequate [3] |
| Bile leak | From the cut surface of the liver or from the hepaticojejunostomy anastomosis |
| Intra-abdominal haemorrhage | Raw cut surface of liver; vascular pedicle bleeding |
| Subphrenic / perihepatic abscess | Bile leak → secondary infection; dead space after resection |
| Portal vein thrombosis | Sluggish flow in the residual portal system post-resection; hypercoagulable state from malignancy |
| Complication | Mechanism |
|---|---|
| Bile duct injury | Especially during radical cholecystectomy near the hepatoduodenal ligament |
| Bile leak from liver bed | Raw surface after wedge resection of segments IVb/V |
| Port-site recurrence | Open approach recommended because laparoscopic bile spillage can seed port sites [10] |
| Peritoneal recurrence | Bile spillage during surgery disseminates tumour cells |
| Pathophysiological Basis | Complications |
|---|---|
| Biliary stasis + loss of barrier | Cholangitis, biliary sepsis, liver abscess |
| Bile acid toxicity | Hepatocyte necrosis → liver failure; cholemic nephrosis → renal failure |
| Fat-soluble vitamin malabsorption | Coagulopathy (Vit K), osteomalacia (Vit D), night blindness (Vit A) |
| Cancer cachexia + malnutrition | Poor wound healing, immunosuppression, muscle wasting, death |
| Tumour local effects | GOO (duodenal compression), pancreatitis (pancreatic duct obstruction), portal vein thrombosis (venous invasion) |
| Metastatic complications | Liver failure (hepatic metastases), ascites (peritoneal carcinomatosis), pathological fractures (bone metastases), respiratory failure (lung metastases) |
| Procedure-related | ERCP: pancreatitis, bleeding, cholangitis, perforation. PTBD: haemobilia, sepsis, fluid loss. Stent: occlusion, migration |
| Surgery-related | Anastomotic leak (PJ > CJ > GJ), pancreatic fistula, DGE, PHLF, bile leak, haemorrhage, renal failure |
The prognosis of MBO depends entirely on the underlying malignancy, but overall it is grim [7]:
| Cancer | Prognosis |
|---|---|
| CA pancreas | Highly lethal malignancy [7]; only 8% diagnosed at localised stage; 5-year survival after Whipple: 25–30% (node-negative), 10% (node-positive) [7]; Median survival for unresectable locally advanced disease: 12 months; metastatic disease: 6 months [7] |
| Cholangiocarcinoma | Only 10% operable at presentation [3]; 5-year survival after R0 resection: 20–40% |
| CA gallbladder | Very poor prognosis: most discovered late and unresectable at diagnosis — 5-year OS < 5% [10] |
| CA ampulla | Best prognosis among periampullary CAs (presents earliest); 5-year survival after Whipple: 40–60% |
| HCC | Variable depending on stage; BCLC staging guides treatment |
High Yield Summary
-
Causes of mortality in MBO: biliary sepsis, cancer cachexia, liver failure [9].
-
Biliary sepsis arises from bile stasis + loss of biliary barrier + immunosuppression. Antibiotic excretion is impaired in biliary obstruction → biliary drainage is mandatory [29]. Normal biliary pressure 7–14 cmH₂O; when > 25 cmH₂O → cholangiovenous/lymphatic reflux → bacteraemia.
-
Pathophysiological effects of MBO: Impaired protein synthesis, impaired clotting factor synthesis, impaired gluconeogenesis, impaired ketogenesis, endotoxaemia, ↓ reticuloendothelial function, ↓ cell-mediated immunity [30].
-
Six measures to reduce surgical complications in MBO: (1) Nutritional support, (2) Vitamin K, (3) FFP during surgery, (4) Antibiotic cover, (5) Mannitol + dopamine to prevent renal failure, (6) H₂ antagonist [32].
-
Stent complications: Occlusion (sludge, tumour ingrowth, tumour overgrowth), migration, cholangitis/cholecystitis [5] [3]. Metal stents last 15–39 weeks; plastic 7–20 weeks [33].
-
PTBD complications: Cholangitis/biliary sepsis, haemobilia (do NOT remove catheter immediately if bleeding — clamp → cholangiogram → slow removal) [5].
-
Post-Whipple: Anastomotic leak (PJ 30% > CJ > GJ), pancreatic fistula (drain amylase > 3× ULN after Day 3), DGE, GDA pseudoaneurysm haemorrhage [14]. Octreotide does NOT reduce pancreatic fistula risk [14].
-
Historical post-op mortality for MBO was ~26–28% [35]; modern mortality at high-volume centres is 2–5% but morbidity remains 30–50%.
-
Prognosis: Pancreatic CA is highly lethal — 5-year survival 25–30% (node-negative Whipple), 10% (node-positive); median survival 12 months (locally advanced), 6 months (metastatic) [7].
Active Recall - Complications of MBO
References
[3] Senior notes: maxim.md, Cholangiocarcinoma management section [5] Senior notes: felixlai.md, Malignant biliary obstruction section (pp. 504–507) [7] Senior notes: felixlai.md, Pancreatic cancer prognosis section (p. 602) [9] Lecture slides: Malignant biliary obstruction.pdf, p29 [10] Senior notes: maxim.md, CA gallbladder section [13] Senior notes: felixlai.md, Acute cholangitis section (pp. 520–522) [14] Senior notes: maxim.md, Pancreatic carcinoma section — Whipple complications and pancreatic fistula (pp. 147–148) [24] Lecture slides: WCS 056 - Painless jaundice and epigastric mass - by Prof R Poon.ppt (1).pdf, p63 [25] Lecture slides: WCS 056 - Painless jaundice and epigastric mass - by Prof R Poon.ppt (1).pdf, p67 [27] Senior notes: maxim.md, ERCP complications section [29] Lecture slides: Malignant biliary obstruction.pdf, p16 [30] Lecture slides: WCS 056 - Painless jaundice and epigastric mass - by Prof R Poon.ppt (1).pdf, p64 [31] Lecture slides: Malignant biliary obstruction.pdf, p24 [32] Lecture slides: WCS 056 - Painless jaundice and epigastric mass - by Prof R Poon.ppt (1).pdf, p66 [33] Lecture slides: Malignant biliary obstruction.pdf, p36 [34] Lecture slides: Malignant biliary obstruction.pdf, p26 [35] Lecture slides: WCS 056 - Painless jaundice and epigastric mass - by Prof R Poon.ppt (1).pdf, p62
High Yield Summary
-
Definition: MBO = obstruction of the biliary tract by cancer growth within or around it. Painless progressive obstructive jaundice in elderly = MBO until proven otherwise.
-
Key Causes (from lecture slides): CA duodenum, periampullary CA, CA pancreas, lymphoma, CA gallbladder (cystic duct LN, direct CBD infiltration, tumour fragments), cholangiocarcinoma at hilum (Klatskin tumour), HCC (direct infiltration, compression, tumour fragments in CBD).
-
Anatomy: Know the biliary tree from intrahepatic ducts → CHD → CBD → Ampulla of Vater. Level of obstruction determines clinical features and imaging findings.
-
Pathophysiology of obstruction: Bile stasis → jaundice, dark urine, pale stool, steatorrhoea, fat-soluble vitamin malabsorption (especially Vitamin K → coagulopathy), loss of biliary barrier → cholangitis/sepsis, impaired immunity, poor wound healing, renal vulnerability.
-
Causes of mortality in MBO: biliary sepsis, cancer cachexia, liver failure.
-
Courvoisier's Law: In painless jaundice + palpable GB → unlikely gallstones → think MBO. Exceptions: double impaction, Mirizzi syndrome, RPC.
-
Clinical differentiation: Stone = painful, fluctuating jaundice, fever. Tumour = painless, progressive jaundice, weight loss, palpable GB.
-
Bismuth-Corlette: Classification of perihilar cholangiocarcinoma (Types I–IV) — essential for surgical planning.
-
Jaundice + epigastric mass: Hepatomegaly (obstruction/metastases/HCC), porta hepatis lymphadenopathy, distended stomach from duodenal obstruction.
-
MBO patients are high-risk surgical candidates due to coagulopathy, immunosuppression, poor wound healing, renal vulnerability, malnutrition, and liver dysfunction.
High Yield Summary
-
Systematic approach: Jaundice → Pre-hepatic/Hepatic/Obstructive (urine + stool colour) → If obstructive: Benign (stone) vs Malignant (tumour) → Level of obstruction (hilar/mid/distal) → Specific cause.
-
Differential of obstructive jaundice: Intraluminal (stone, RPC), Mural (cholangiocarcinoma, PSC), Extramural (CA head pancreas, lymphadenopathy, Mirizzi's) [2].
-
Stone vs Tumour: Stone = painful, fluctuating jaundice, fever, GB NOT palpable. Tumour = painless, progressive jaundice, weight loss, GB palpable (Courvoisier's).
-
Malignant causes from lecture: CA duodenum, periampullary CA, CA pancreas, lymphoma, CA gallbladder, cholangioCA/Klatskin tumour, HCC [1].
-
Level of obstruction on imaging: Hilar (intrahepatic dilatation only → Klatskin, CA GB, HCC), Mid-CBD (CA CBD, CA pancreas head, LN), Distal (periampullary CA → GB distended).
-
Jaundice + epigastric mass: Hepatomegaly (obstruction/metastases/HCC), porta hepatis LN metastases, CA stomach with porta LN, distended stomach from duodenal obstruction [11].
-
Tumour markers (CA 19-9, CEA, AFP) are neither sensitive nor specific — absence does NOT exclude malignancy; presence does NOT confirm it [5] [18].
-
Must-exclude benign mimics: Mirizzi syndrome, PSC, IgG4-related cholangitis, autoimmune pancreatitis, choledochal cysts — all can mimic MBO on imaging.
High Yield Summary
-
MBO management starts with: (1) Establish diagnosis, (2) Delineate level and cause, (3) Treat cholangitis, (4) Definitive treatment [20].
-
Physical exam: Always check for Courvoisier's sign and signs of inoperability (Virchow's node, Blumer's shelf, Sister Mary Joseph nodule, irregular hepatomegaly, ascites) [5].
-
Bloods: Cholestatic LFT pattern (↑ ALP, GGT, conjugated bilirubin); clotting profile (Vitamin K deficiency); tumour markers are NOT diagnostic — neither sensitive nor specific [5] [18].
-
USG is the first-line imaging — establishes duct dilatation, level, stones vs no stones. CBD > 0.8 cm is pathological; intrahepatic ducts normally not visible ( < 2–3 mm) [5].
-
CT triphasic (pancreatic protocol) is the definitive staging investigation — identifies mass, vascular involvement (resectability), LN, metastases [7] [14].
-
Cholangiography: MRCP for non-invasive biliary mapping; ERCP for distal obstruction (diagnostic + therapeutic); PTC for proximal/hilar obstruction [3] [20].
-
Tissue diagnosis is NOT mandatory if tumour is resectable — proceed to surgery. Tissue diagnosis needed for: uncertain diagnosis, neoadjuvant chemo, unresectable disease, suspected mimics (autoimmune pancreatitis, IgG4 cholangitis) [7] [14].
-
EUS-FNAC is preferred over percutaneous biopsy (lower tumour seeding risk) [14]; EUS has NO role for CA ampulla or CA duodenum (use OGD) [5].
-
Staging: CT TAP/PET-CT for distant mets; staging laparoscopy if high suspicion of peritoneal disease [7].
-
Unresectability criteria: Major vessel encasement (SMA, celiac, PV, SMV), bilateral biliary involvement > 2° radicles, distant LN (retropancreatic, paracoeliac, paraaortic), organ metastasis [3] [14].
High Yield Summary
-
Management framework: Treat sepsis → Assess (general status + tumour status) → Resectable + Fit → Laparotomy; Unresectable or Unfit → Palliation [20] [22].
-
MBO is high-risk for surgery because of: cancer cachexia → malnutrition, liver function impairment, superimposed biliary infection [24].
-
Pre-op measures: IV Vitamin K + FFP (coagulopathy), nutritional support (cachexia), antibiotics (infection), pre-op biliary drainage (target bilirubin < 50 µmol/L; < 20 µmol/L if hepatectomy planned) [25].
-
QMH practice: Drain ALL patients pre-op because Whipple wait time is 6–8 weeks [5].
-
ERCP with endoprosthesis is ALWAYS 1st line for biliary drainage; PTBD if ERCP fails/contraindicated [5].
-
Metallic stents for confirmed inoperable disease (durable, longer patency, cannot be removed); plastic stents for temporary pre-op drainage (removable) [3] [5].
-
Curative surgery by pathology: Periampullary → Whipple; CA GB → Radical cholecystectomy; Klatskin → Major hepatectomy + caudate; Intrahepatic CC → Partial hepatectomy; Distal CC → Whipple [5] [3].
-
Palliative bypass: Single (hepaticojejunostomy), Double (+ gastrojejunostomy for GOO), Triple (+ pancreaticojejunostomy — high leak risk) [5].
-
Stent/PTBD vs Surgical bypass: Stent = lower initial morbidity, more re-interventions; Surgery = higher initial morbidity, better long-term results [28].
-
Role of surgery: Oncological clearance (R0 resection), relieve obstruction, pain control [26]. Portal vein involvement is NOT an absolute contraindication [5].
High Yield Summary
-
Causes of mortality in MBO: biliary sepsis, cancer cachexia, liver failure [9].
-
Biliary sepsis arises from bile stasis + loss of biliary barrier + immunosuppression. Antibiotic excretion is impaired in biliary obstruction → biliary drainage is mandatory [29]. Normal biliary pressure 7–14 cmH₂O; when > 25 cmH₂O → cholangiovenous/lymphatic reflux → bacteraemia.
-
Pathophysiological effects of MBO: Impaired protein synthesis, impaired clotting factor synthesis, impaired gluconeogenesis, impaired ketogenesis, endotoxaemia, ↓ reticuloendothelial function, ↓ cell-mediated immunity [30].
-
Six measures to reduce surgical complications in MBO: (1) Nutritional support, (2) Vitamin K, (3) FFP during surgery, (4) Antibiotic cover, (5) Mannitol + dopamine to prevent renal failure, (6) H₂ antagonist [32].
-
Stent complications: Occlusion (sludge, tumour ingrowth, tumour overgrowth), migration, cholangitis/cholecystitis [5] [3]. Metal stents last 15–39 weeks; plastic 7–20 weeks [33].
-
PTBD complications: Cholangitis/biliary sepsis, haemobilia (do NOT remove catheter immediately if bleeding — clamp → cholangiogram → slow removal) [5].
-
Post-Whipple: Anastomotic leak (PJ 30% > CJ > GJ), pancreatic fistula (drain amylase > 3× ULN after Day 3), DGE, GDA pseudoaneurysm haemorrhage [14]. Octreotide does NOT reduce pancreatic fistula risk [14].
-
Historical post-op mortality for MBO was ~26–28% [35]; modern mortality at high-volume centres is 2–5% but morbidity remains 30–50%.
-
Prognosis: Pancreatic CA is highly lethal — 5-year survival 25–30% (node-negative Whipple), 10% (node-positive); median survival 12 months (locally advanced), 6 months (metastatic) [7].